EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	409	(544/206).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L2	431	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L3	688	(544/211).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L4	956	(544/212).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:08
L5	0	chi.inv. adj "Vu.inv" and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L6	0	chi.inv. adj vu.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L7	1	chi.inv. and vu.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L8	2	chi.inv. and vu.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:10
L9	0	Russell.inv. and Peter.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:10
L10	0	Gnanasambandam.inv. and Kumarsvel.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:11
L11	0	Gnanasambandam.inv. and Kumarsvel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:11

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	409	(544/206).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L2	431	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L3	688	(544/211).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:07
L4	956	(544/212).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:08
L5	0	chi.inv. adj "Vu.inv" and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L6	0	chi.inv. adj vu.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L7	1	chi.inv. and vu.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:09
L8	2	chi.inv. and vu.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:10
L9	0	Russell.inv. and Peter.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:10
L10	0	Gnanasambandam.inv. and Kumarsvel.inv. and triazolo	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:11
L11	0	Gnanasambandam.inv. and Kumarsvel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/27 14:11

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:04:46 ON 27 NOV 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:05:07 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4
DICTIONARY FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\105523032.str

C:\Program Files\Stnexp\Queries\10552303.str





chain nodes :
10 12
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-10
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 12:CLASS
Generic attributes :
10:
Saturation : Unsaturated

C:\Program Files\Stnexp\Queries\105523032.str





chain nodes :
10 12 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14 4-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-10
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 12:CLASS 14:Atom
Generic attributes :
10:
Saturation : Unsaturated





chain nodes :
10 12 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14 4-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-10
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 14:Atom
Generic attributes :
10:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:05:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      115 TO ITERATE

100.0% PROCESSED      115 ITERATIONS                          11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1657 TO     2943
PROJECTED ANSWERS:              21 TO      417

L2            11 SEA SSS SAM L1

=> d scan
```

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (9CI)
MF C24 H19 N13 O3

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(3-pyridinylmethyl)- (9CI)
MF C15 H13 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,3-difluorophenyl)methyl]-3-piperidinyl]methyl]-2-(2-furanyl)- (9CI)
MF C21 H22 F2 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI)
MF C16 H22 N8 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI)
MF C19 H21 N9 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phenol, 2-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI)
MF C17 H16 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (9CI)
MF C23 H21 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-propyl- (9CI)
MF C11 H13 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(4-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI)
MF C21 H24 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI)
MF C20 H21 Cl N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phenol, 4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino]ethyl]- (9CI)
MF C16 H15 N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 sss ful
FULL SEARCH INITIATED 12:06:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2376 TO ITERATE

100.0% PROCESSED     2376 ITERATIONS                                319 ANSWERS
SEARCH TIME: 00.00.01

L3          319 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     167.38     167.59

FILE 'CAPLUS' ENTERED AT 12:06:12 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Nov 2006  VOL 145 ISS 23
FILE LAST UPDATED: 26 Nov 2006  (20061126/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          126 L3

=> d l4 1-126 bib hitstr
```

L4 ANSWER 1 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1047255 CAPLUS
DN 145:353569
TI Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction
AU Faria, Miguel; Magalhaes-Cardoso, Teresa; Lafuente-de-Carvalho, Jose-Maria; Correia-de-Sa, Paulo
CS Laboratorio de Farmacologia, Unidade Multidisciplinar de Investigacao Biomedica, Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto, Oporto, Port.
SO Journal of Pharmacology and Experimental Therapeutics (2006), 319(1), 405-413
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
(corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1009835 CAPLUS
DN 145:369892
TI Adenosine 2a receptor signaling modulators for the treatment of HIV-associated neuronal damage
IN Dewhurst, Stephen; Ramirez, Servio; Lu, Shao-Ming; Gelbard, Harris A.; Maggirwar, Sanjay B.; Fan, Shongshan
PA University of Rochester, USA
SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006101920	A2	20060928	WO 2006-US9390	20060316

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-663059P P 20050318
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine 2a receptor signaling modulators for treatment of HIV-associated neuronal damage)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:933602 CAPLUS
DN 145:416903
TI A2A adenosine receptor protects tumors from antitumor T cells
AU Ohta, Akio; Gorelik, Elieser; Prasad, Simon J.; Ronchese, Franca; Lukashev, Dmitriy; Wong, Michael K. K.; Huang, Xiaojun; Caldwell, Sheila; Liu, Kebin; Smith, Patrick; Chen, Jiang-Fan; Jackson, Edwin; Apasov, Sergey; Abrams, Scott; Sitkovsky, Michail
CS Lab. Immunol., Natl. inst. Allergy and Infectious Diseases, Natl. Inst. Health, Bethesda, MD, 20892, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2006), 103(35), 13132-13137
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT 139180-30-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor protects tumors from antitumor T cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:883497 CAPLUS
DN 145:328753
TI Expression and functional purification of a glycosylation deficient version of the human adenosine 2a receptor for structural studies
AU Fraser, Niall J.
CS Division of Biochemistry and Molecular Biology, IBLS, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
SO Protein Expression and Purification (2006), 49(1), 129-137
CODEN: PEXPEJ; ISSN: 1046-5928
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(expression/purification of a glycosylation deficient version of human adenosine 2A receptor and their dynamic binding to selected antagonists and agonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:837021 CAPLUS
DN 145:285428
TI Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells
AU Li, Y.; Oskouian, R. J.; Day, Y.-J.; Rieger, J. M.; Liu, L.; Kern, J. A.; Linden, J.
CS Department of Medicine, University of Virginia Health System, Charlottesville, VA, 22908, USA
SO Neuroscience (San Diego, CA, United States) (2006), 141(4), 2029-2039
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A2A receptor agonist; mouse spinal cord compression injury is reduced by either activation of adenosine A2A receptor on bone marrow-derived cells or deletion of A2A receptor on non-bone marrow-derived cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:790659 CAPLUS
DN 145:202900
TI Sepsis prevention through adenosine receptor modulation
IN Hasko, Gyorgy; Nemeth, Zoltan; Bleich, David; Deitch, Edwin
PA University of Medicine and Dentistry of New Jersey, USA
SO PCT Int. Appl., 45pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006083949	A2	20060810	WO 2006-US3523	20060201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-648809P P 20050201
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sepsis prevention through adenosine receptor modulation)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:756818 CAPLUS
DN 145:203066
TI Functional coupling of the Gαolf variant XLGαolf with the human adenosine A2A receptor
AU Ravyn, Vipa; Bostwick, J. Robert
CS Lead Discovery, AstraZeneca Pharmaceuticals, Wilmington, DE, USA
SO Journal of Receptors and Signal Transduction (2006), 26(4), 241-258
CODEN: JRSTCT
PB Taylor & Francis, Inc.
DT Journal
LA English
IT 904875-36-1
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(functional coupling of Gαolf variant XLGαolf with the human adenosine A2A receptor)
RN 904875-36-1 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-, labeled with tritium (9CI) (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:736180 CAPLUS
DN 145:180997
TI mitochondrial hyperpolarization inhibitors for treatment of HIV neurotoxin-induced neurol. disease
IN Perry, Seth W.; Norman, John Phillip; Dewhurst, Stephen; Gelbard, Harris A.
PA University of Rochester, USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006078876	A2	20060727	WO 2006-US1987	20060119
WO 2006078876	C2	20060928		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-645426P P 20050120
US 2005-663424P P 20050318

IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mitochondrial hyperpolarization inhibitors for treatment of HIV neurotoxin-induced neurol. disease)

RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:628111 CAPLUS
DN 145:96747
TI Characterization of [125I]ZM 241385 binding to adenosine A2A receptors in the pineal of sheep brain
AU Yan, X.; Koos, B. J.; Kruger, L.; Linden, J.; Murray, T. F.
CS Department of Pharmacology, Creighton University School of Medicine, Omaha, NE, 68178, USA
SO Brain Research (2006), 1096(1), 30-39
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6D, ZM 241385, iodo derivs., iodine-125 labeled
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
(characterization of [125I]ZM 241385 binding to adenosine A2A receptors in pineal of sheep brain in relation to melatonin secretion)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:596148 CAPLUS
DN 145:160045
TI Adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in the globus pallidus of the rat
AU Gonzalez, Brenda; Paz, Francisco; Floran, Leonor; Aceves, Jorge; Erlij, David; Floran, Benjamin
CS Biofisica y Neurociencias, Centro de Investigacion y de Estudios Avanzados, Departamento de Fisiologia, Mexico City, 07000, Mex.
SO Neuropharmacology (2006), 51(1), 154-159
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(A2A antagonist; adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in globus pallidus of rat through mechanism involving protein kinase A)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:107465 CAPLUS
DN 144:286058
TI The effect of intraentorhinal injection of selective A2A receptor agonist on pyriform cortex-kindled seizures in rats
AU Hosseinmardi, N.; Mirnajafi-Zadeh, J.; Fathollahi, Y.; Shahabi, P.; Rezvani, M. E.; Namvar, S.
CS Dept. Physiol., Sch. Med. Sci., Tarbiat Modares Univ., Tehran, Iran
SO Fiziolozhi va Farmakolozhi (2005), 9(1), 41-46
CODEN: PPHHAM; ISSN: 1735-0581
PB Iranian Society of Physiology and Pharmacology
DT Journal
LA Persian
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(effect of intraentorhinal injection of selective A2A receptor agonist on pyriform cortex-kindled seizures in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:75101 CAPLUS
DN 144:143078
TI Antagonizing an adenosine A2A receptor to amelioriate one or more components of addictive behavior
IN Diamond, Ivan F.; Gordon, Adrienne S.
PA The Regents of the University of California, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006009698	A2	20060126	WO 2005-US20992	20050614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006128708	A1	20060615	US 2005-153725	20050614
PRAI US 2004-581143P	P	20040617		

IT 139180-30-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonists for amelioriation of one or more components of addictive behavior)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1218618 CAPLUS
DN 143:472578
TI Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
IN Okusa, Mark D.; Linden, Joel M.; MacDonald, Timothy L.; Awad, Alaa S.
PA University of Virginia Patent Foundation, USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005107463	A1	20051117	WO 2005-US15241	20050503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005261236	A1	20051124	US 2005-121169	20050503
PRAI	US 2004-567465P	P	20040503		

OS MARPAT 143:472578
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor agonists for treatment of diabetic nephropathy)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:978112 CAPLUS
DN 144:122110
TI Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test
AU Kaster, Manuella P.; Santos, Adair R. S.; Rodrigues, Ana L. S.
CS Departamento de Bioquimica, Centro de Ciencias Biologicas, Universidade Federal de Santa Catarina, Florianopolis, 88040-900, Brazil
SO Brain Research Bulletin (2005), 67(1-2), 53-61
CODEN: BRBUDU; ISSN: 0361-9230
PB Elsevier Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:520544 CAPLUS
DN 143:339402
TI Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats
AU Prediger, R. D. S.; Da Cunha, C.; Takahashi, R. N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas Universidade Federal de Santa Catarina, UFSC, Universidade Federal de Santa Catarina, UFSC, Brazil
SO Behavioural Pharmacology (2005), 16(4), 209-218
CODEN: BPHAEL; ISSN: 0955-8810
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reserpine induced social recognition disruption was reversed by acute treatment with adenosine A2A receptor antagonist ZM241385 and 'non-effective' doses of ZM241385 combined with quinpirole showed synergistic response in rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:495122 CAPLUS
DN 143:146976
TI Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20
AU Gessi, Stefania; Varani, Katia; Merighi, Stefania; Cattabriga, Elena; Pancaldi, Cecilia; Szabadkai, Youri; Rizzuto, Rosario; Klotz, Karl-Norbert; Leung, Edward; Mac Lennan, Stephen; Baraldi, Pier Giovanni; Borea, Pier Andrea
CS Department of Clinical and Experimental Medicine, Pharmacology Unit, University of Ferrara, Italy
SO Molecular Pharmacology (2005), 67(6), 2137-2147
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU'(Biological study, unclassified); BIOL (Biological study)
(A2B antagonist; expression, pharmacol. profile, and functional coupling of A2B receptors in recombinant system and in peripheral blood cells using novel selective antagonist radioligand, [3H]MRE 2029-F20)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:442161 CAPLUS
DN 143:278709
TI Involvement of Adenosine in the Antiinflammatory Action of Ketamine
AU Mazar, Julia; Rogachev, Boris; Shaked, Gad; Ziv, Nadav Y.; Czeiger, David; Chaimovitz, Cidio; Zlotnik, Moshe; Mukmenev, Igor; Byk, Gerardo; Douvdevani, Amos
CS Department of Nephrology, Sorokaa University Medical Center, Ben-Gurion University of The Negev, Beer-Sheve, Israel
SO Anesthesiology (2005), 102(6), 1174-1181
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(adenosine receptor antagonist DMPX and ZM 241385 blocked anti-inflammatory effects in mouse peritonitis model)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:442159 CAPLUS
DN 143:279038
TI Effect of Sleep Deprivation on Righting Reflex in the Rat Is Partially Reversed by Administration of Adenosine A1 and A2 Receptor Antagonists
AU Tung, Avery; Herrera, Stacy; Szafran, Martin J.; Kasza, Kristen; Mendelson, Wallace B.
CS Department of Anesthesia and Critical Care, Biostatistics, and Psychiatry, the University of Chicago, Chicago, IL, USA
SO Anesthesiology (2005), 102(6), 1158-1164
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2a receptor antagonist ZM241385 partially reversed effect of sleep deprivation on isoflurane-induced loss of righting reflex and dose dependently shortened time of recovery in sleep deprived rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:413328 CAPLUS
DN 143:38317
TI Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1
AU Desai, Avani; Victor-Vega, Cassandre; Gadangi, Swathi; Montesinos, M. Carmen; Chu, Charles C.; Cronstein, Bruce N.
CS Department of Medicine, New York University School of Medicine, New York, NY, USA
SO Molecular Pharmacology (2005), 67(5), 1406-1413
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(adenosine A2A receptor stimulation increases angiogenesis by down-regulating thrombospondin 1)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:387578 CAPLUS
DN 143:380086
TI Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. [Erratum to document cited in CA142:310219]
AU Uustare, Ain; Vonk, Argo; Terasmaa, Anton; Fuxe, Kjell; Rinken, Ago
CS Institute of Organic and Bioorganic Chemistry, University of Tartu, Tartu, EE-51014, Estonia
SO Life Sciences (2005), 77(3), 359
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinetic and functional properties of high affinity antagonist [3H]ZM241385 for adenosine A2A receptors (Erratum))
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:326031 CAPLUS
DN 143:146380
TI Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats
AU Prediger, Rui D. S.; Fernandes, Daniel; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, Universidade Federal de Santa Catarina, Florianopolis, 88049-900, Brazil
SO Behavioural Brain Research (2005), 159(2), 197-205
CODEN: BBREDI; ISSN: 0166-4328
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adenosine A2A receptor antagonist ZM241385 reversed social memory impairment in spontaneously hypertensive rat indicating involvement of adenosine A2A receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:163161 CAPLUS
DN 142:348881
TI Effects of adenosine and adenosine A2A receptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy
AU Kumar, Sokindra; Arun, K. H. S.; Kaul, Chaman L.; Sharma, Shyam S.
CS Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Punjab, India
SO Neurological Research (2005), 27(1), 60-66
CODEN: NRESDZ; ISSN: 0161-6412
PB Maney Publishing
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CGS 21680 hydrochloride failed to produce protective effect on sciatic MNCV but improved NBF in diabetic rat model was inhibited by adenosine A2A receptor antagonist ZM 241385 suggesting involvement of adenosine receptor mechanism in DN)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:160837 CAPLUS
DN 142:233372
TI Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal
IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005043327	A1	20050224	US 2004-870209	20040617
	CA 2536280	AA	20050303	CA 2004-2536280	20040809
	WO 2005018645	A1	20050303	WO 2004-IB2596	20040809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1658082	A1	20060524	EP 2004-744231	20040809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013693	A	20061024	BR 2004-13693	20040809
PRAI	US 2003-496803P	P	20030821		
	WO 2004-IB2596	W	20040809		

IT 736993-82-1 736993-84-3 736993-86-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)
RN 736993-82-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, N-butyl-7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 736993-84-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-

chlorophenyl)-N-[2-(4-fluorophenyl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 736993-86-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:149004 CAPLUS
DN 142:456798
TI Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats
AU Prediger, Rui D. S.; Batista, Luciano C.; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, UFSC, Campus Trindade, Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, 88049-900, Brazil
SO Neurobiology of Aging (2005), 26(6), 957-964
CODEN: NEAGDO; ISSN: 0197-4580
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(acute ZM241385 reversed age-related olfactory discrimination and social recognition memory in rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:137653 CAPLUS
DN 142:255028
TI Modulation of short-term social memory in rats by adenosine A1 and A2A receptors
AU Prediger, Rui D. S.; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, Universidade Federal de Santa Catarina, UFSC, Florianopolis, 88049-900, Brazil
SO Neuroscience Letters (2005), 376(3), 160-165
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(adenosine A1 and A2A receptor modulation of short-term social memory in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:70069 CAPLUS
DN 142:310219
TI Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors
AU Uustare, Ain; Vonk, Argo; Terasmaa, Anton; Fuxe, Kjell; Rinken, Ago
CS Institute of Organic and Bioorganic Chemistry, University of Tartu, Tartu, EE-51014, Estonia
SO Life Sciences (2005), 76(13), 1513-1526
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinetic and functional properties of high affinity antagonist [3H]ZM241385 for adenosine A2A receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:8089 CAPLUS
DN 142:232790
TI A2A adenosine receptor induction inhibits IFN-γ production in murine CD4+ T cells
AU Lappas, Courtney M.; Rieger, Jayson M.; Linden, Joel
CS Department of Pharmacology, University of Virginia, Charlottesville, VA, 22908, USA
SO Journal of Immunology (2005), 174(2), 1073-1080
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor induction inhibits IFN-γ production in murine CD4+ T cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1050225 CAPLUS
DN 142:211236
TI Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows
AU Popoli, Patrizia; Minghetti, Luisa; Tebano, Maria Teresa; Pintor, Annita; Domenici, Maria Rosaria; Massotti, Marino
CS Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
SO Critical Reviews in Neurobiology (2004), 16(1&2), 99-106
CODEN: CCNBE8; ISSN: 0892-0915
PB Begell House, Inc.
DT Journal; General Review
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A2A receptor antagonist ZM 241385 may have either potentially beneficial or detrimental influence in neurodegenerative mouse models that are mainly due to increased glutamate levels or enhanced sensitivity of NMDA receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:913079 CAPLUS
DN 142:48803
TI Modification of cytokine milieu by A2A adenosine receptor signaling-possible application for inflammatory diseases
AU Koshiba, M.; Nakamachi, Y.; Kosaka, H.; Nakazawa, T.; Tsuji, G.; Kumagai, S.
CS Clinical Pathology and Immunology, Department Biomedical Informatics, Kobe University Graduate School of Medicine, Kobe, Japan
SO Nucleosides, Nucleotides & Nucleic Acids (2004), 23(8 & 9), 1101-1106
CODEN: NNNAFY; ISSN: 1525-7770
PB Marcel Dekker, Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(modification of cytokine milieu by A2A adenosine receptor signaling)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:908902 CAPLUS
DN 142:93773
TI Novel Bicyclic Piperazine Derivatives of Triazolotriazine and Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor Antagonists
AU Peng, Hairuo; Kumaravel, Gnanasambandam; Yao, Gang; Sha, Li; Wang, Joy; Van Vlijmen, Herman; Bohnert, Tonika; Huang, Carol; Vu, Chi B.; Ensinger, Carol L.; Chang, Hexi; Engber, Thomas M.; Whalley, Eric T.; Petter, Russell C.
CS Departments of Medicinal Chemistry, Pharmacology, and Computational Drug Design, Biogen Idec Inc., Cambridge, MA, 02142, USA
SO Journal of Medicinal Chemistry (2004), 47(25), 6218-6229
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:93773
IT 781638-61-7P 781638-65-1P 816429-49-9P
816429-51-3P 816429-55-7P 816429-57-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyridopyrazine derivs. of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists)
RN 781638-61-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(7R,9aR)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781638-65-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(7R,9aS)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 816429-49-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aS)-2-(3,5-difluorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 816429-51-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aS)-2-[(2,4-difluorophenyl)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 816429-55-7 CAPLUS
CN Pyrazinecarboxylic acid, 3-amino-5-[(7R,9aS)-7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-6-chloro-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 816429-57-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aR)-2-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 816429-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridopyrazine derivs. of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists)
RN 816429-65-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid, 7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-, 1,1-dimethylethyl ester, (7R,9aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:908013 CAPLUS
DN 142:1190
TI Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor
AU Torvinen, Maria; Kozell, Laura B.; Neve, Kim A.; Agnati, Luigi F.; Fuxe, Kjell
CS Department of Neuroscience, Karolinska Institute, Stockholm, 171 77, Swed.
SO Journal of Molecular Neuroscience (2004), 24(2), 173-180
CODEN: JMNEES; ISSN: 0895-8696
PB Humana Press Inc.
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(biochem. identification of dopamine D2 receptor domains interacting with the adenosine A2A receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:902383 CAPLUS
DN 141:379947
TI Preparation of triazolotriazines and related derivatives as A2a adenosine receptor antagonists
IN Peng, Hairuo; Yao, Gang; Vu, Chi; Petter, Russell C.; Kumaravel, Gnanasambandam
PA Biogen Idec Ma Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004092173	A2	20041028	WO 2004-US11009	20040409
WO 2004092173	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633756	A2	20060315	EP 2004-759359	20040409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-461484P	P	20030409		
WO 2004-US11009	W	20040409		

OS MARPAT 141:379947
IT 781638-61-7P 781638-63-9P 781638-65-1P
781639-70-1P 781639-71-2P 781639-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolotriazines and related derivs. as A2a adenosine receptor antagonists for the treatment of, e.g., Parkinson's disease)
RN 781638-61-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(7R,9aR)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781638-63-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aS)-2-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781638-65-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(7R,9aS)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781639-70-1 CAPLUS

CN Pyrazinecarboxylic acid, 3-amino-6-chloro-5-[(7R,9aR)-7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781639-71-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aR)-2-(3,5-difluorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 781639-73-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(7R,9aR)-2-[(2,4-difluorophenyl)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 781640-34-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolotriazines and related derivs. as A2a adenosine receptor antagonists for the treatment of, e.g., Parkinson's disease)
RN 781640-34-4 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid, 7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-, 1,1-dimethylethyl ester, (7R,9aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 33 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:902380 CAPLUS
DN 141:395582
TI Preparation of triazolotriazines and pyrazolotriazines as A2a adenosine receptor antagonists for the treatment of Parkinson's disease
IN Vu, Chi; Petter, Russell C.; Kumaravel, Gnanasambandam
PA Biogen Idec Ma Inc., USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092170	A2	20041028	WO 2004-US11005	20040409
	WO 2004092170	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1615930	A2	20060118	EP 2004-759355	20040409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-461356P	P	20030409		
	WO 2004-US11005	W	20040409		

OS MARPAT 141:395582
IT 745072-66-6P 745072-67-7P 745072-68-8P
745072-69-9P 745072-70-2P 745072-73-5P
745072-74-6P 745072-75-7P 745072-76-8P
745072-80-4P 745073-05-6P 760988-74-7P
760988-77-0P 760988-81-6P 760995-64-0P
785823-63-4P 785823-71-4P 785823-73-6P
785823-75-8P 785823-79-2P 785823-84-9P
785823-85-0P 785823-93-0P 785823-97-4P
785824-08-0P 785824-11-5P 785824-13-7P
785824-15-9P 785824-21-7P 785824-22-8P
785824-23-9P 785824-24-0P 785824-25-1P
785824-26-2P 785824-37-5P 785824-38-6P
785824-45-5P 785824-46-6P 785824-47-7P
785824-48-8P 785824-49-9P 785824-50-2P
785824-51-3P 785824-52-4P 785824-53-5P
785824-54-6P 785824-55-7P 785824-56-8P
785824-57-9P 785824-58-0P 785824-59-1P
785824-60-4P 785824-61-5P 785824-62-6P
785824-63-7P 785824-64-8P 785824-65-9P
785824-66-0P 785824-67-1P 785824-68-2P
785824-69-3P 785824-70-6P 785824-71-7P
785824-72-8P 785824-73-9P 785824-74-0P
785824-75-1P 785824-76-2P 785824-77-3P
785824-78-4P 785824-79-5P 785824-80-8P
785824-81-9P 785824-88-6P 785824-89-7P
785824-90-0P 785824-91-1P 785824-92-2P
785824-93-3P 785825-01-6P 785825-02-7P
785825-03-8P 785825-04-9P 785825-05-0P

785825-07-2P 785825-08-3P 785825-09-4P
785825-10-7P 785825-11-8P 785825-12-9P
785825-13-0P 785825-16-3P 785825-17-4P
785825-18-5P 785825-19-6P 785825-20-9P
785825-21-0P 785825-22-1P 785825-23-2P
785825-24-3P 785825-25-4P 785825-26-5P
785825-27-6P 785825-28-7P 785825-29-8P
785825-30-1P 785825-33-4P 785825-34-5P
785825-35-6P 785826-59-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolotriazines and pyrazolotriazines as A2a adenosine receptor antagonists for the treatment of Parkinson's disease)

RN 745072-66-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-67-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-68-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-69-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[3-[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 745072-70-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2,2-dimethyl-3-[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 745072-73-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 745072-74-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 745072-75-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 745072-76-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 745072-80-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-05-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760988-74-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 760988-77-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 760988-81-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 760995-64-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,6-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 785823-63-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785823-71-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 785823-73-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 785823-75-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 785823-79-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785823-84-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)



RN 785823-85-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785823-93-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 785823-97-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(3-fluorophenyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-08-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-11-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-13-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(3-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-15-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-21-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-bromophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX

NAME)



RN 785824-22-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-23-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-24-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-25-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-26-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-furanylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-37-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chloro-2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-38-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-45-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(2-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-46-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-47-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-6-fluoro-3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-48-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-49-9 CAPLUS
CN Carbamic acid, [2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 785824-50-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-51-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-52-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-53-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-54-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,4-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-55-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(4-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-56-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,5-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-57-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-58-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]methylamino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 785824-59-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-60-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-dimethylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-61-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-3-quinolinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-62-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(5-chloro-2-furanyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-63-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(2,3,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-64-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(2,4,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-65-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(2,4,5-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-66-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 785824-67-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-68-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-chlorophenyl)methyl]-3-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-69-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 785824-70-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 785824-71-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[3-chloro-2-

fluoro-6-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-72-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(3-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-73-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-74-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-fluoro-3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA

INDEX NAME)



RN 785824-75-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-bromo-5-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-76-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-chloro-3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-77-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 785824-78-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chloro-2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-79-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-80-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-81-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(4-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-88-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 785824-89-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chloro-2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



RN 785824-90-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (9CI)

(CA INDEX NAME)



RN 785824-91-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[1-[(2,3,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785824-92-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,3-difluorophenyl)methyl]-3-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785824-93-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-quinolinylmethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-01-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-(2-benzofuranylmethyl)-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-02-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-03-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(4-bromo-1-methyl-1H-pyrazol-3-yl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-04-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-05-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(3-methyl-2-pyridinyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-07-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,6-dichloro-5-fluoro-2-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-08-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,4-dimethyl-3-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-09-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-dichlorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-10-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-6-fluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-11-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-fluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-12-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chlorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-13-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(6-chloro-3-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX

NAME)



RN 785825-16-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chloro-2-fluoro-4-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-17-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-fluoro-5-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-18-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-fluoro-4-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-19-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-bromo-4-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-20-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[1-[(2,4,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-21-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-22-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-quinolinylmethyl)-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-23-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-(2-

pyridinylmethyl)-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-24-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-dichloro-5-fluoro-3-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-25-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3,5-dichloro-4-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-26-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-27-6 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 785825-28-7 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 785825-29-8 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-[1-[(5-methyl-3-isoxazolyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 785825-30-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-methyl-N2-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 785825-33-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-34-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 785825-35-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 785826-59-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(6-chloro-2-fluoro-3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



IT 785825-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolotriazines and pyrazolotriazines as A2a adenosine receptor antagonists for the treatment of Parkinson's disease)
RN 785825-38-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]-,

1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 34 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:892419 CAPLUS
DN 141:360784
TI Characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A receptor knockout mice
AU Kelly, Mary; Bailey, Alexis; Ledent, Catherine; Kitchen, Ian; Hourani, Susanna
CS School of Biomedical and Molecular Sciences, University of Surrey, Surrey, GU2 7XH, UK
SO European Journal of Pharmacology (2004), 504(1-2), 55-59
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6D, ZM 241385, Tritium-labeled
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:729831 CAPLUS
DN 141:271406
TI Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists
AU Vu, Chi B.; Shields, Pamela; Peng, Bo; Kumaravel, Gnanasambandam; Jin, Xiaowei; Phadke, Deepali; Wang, Joy; Engber, Thomas; Ayyub, Eman; Petter, Russell C.
CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA, 02142, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4835-4838
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:271406
IT 760988-72-5P 760988-73-6P 760988-74-7P
760988-76-9P 760988-77-0P 760988-78-1P
760988-79-2P 760988-81-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(triamino derivs. of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists)
RN 760988-72-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 760988-73-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[3-(4-phenyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 760988-74-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 760988-76-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[3-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 760988-77-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 760988-78-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[3-[4-(2,4-difluorophenyl)-1-piperazinyl]propyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 760988-79-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-(4-phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 760988-81-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N5-methyl- (9CI) (CA INDEX NAME)



IT 760988-71-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(triamino derivs. of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists)
RN 760988-71-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(2,2-dimethoxyethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:729830 CAPLUS
DN 141:271008
TI Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles
AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Sha, Li; Kumaravel, Gnanasambandam; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Petter, Russell C.
CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA, 02142, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4831-4834
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:271008
IT 745072-78-0 745072-80-4 745072-82-6
745073-04-5 745073-09-0 745073-10-3
760995-64-0 760995-69-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure activity of adenosine A2a receptor antagonists)
RN 745072-78-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-80-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-82-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-04-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-09-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-10-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760995-64-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,6-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 760995-69-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:681669 CAPLUS
DN 141:185088
TI Inhibitory effects of adenosine receptor antagonists and HTLV-I-cell binding to treat HLV-1 infection
IN Hague, Bishop F.; Zhao, Tong-Mao; Kindt, Thomas J.
PA The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004070000	A2	20040819	WO 2003-US35431	20031030
WO 2004070000	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003291346	A1	20040830	AU 2003-291346	20031030
PRAI US 2002-422803P	P	20021030		
WO 2003-US35431	W	20031030		

IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitory effects of adenosine receptor antagonists and HTLV-I-cell binding to treat HLV-1 infection)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 38 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:654773 CAPLUS
DN 141:190806
TI Preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists
IN Griffith, David A.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 72 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157839	A1	20040812	US 2004-763105	20040121
	AU 2004209447	A1	20040819	AU 2004-209447	20040126
	CA 2513409	AA	20040819	CA 2004-2513409	20040126
	WO 2004069837	A1	20040819	WO 2004-IB269	20040126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1592691	A1	20051109	EP 2004-705138	20040126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006957	A	20060103	BR 2004-6957	20040126
	CN 1768061	A	20060503	CN 2004-80009125	20040126
	JP 2006517203	T2	20060720	JP 2006-500314	20040126
	NL 1025404	A1	20040809	NL 2004-1025404	20040204
	NL 1025404	C2	20050314		
	NO 2005004082	A	20051104	NO 2005-4082	20050902
PRAI	US 2003-445728P	P	20030206		
	WO 2004-IB269	W	20040126		

OS MARPAT 141:190806
IT 736993-82-1P 736993-84-3P 736993-86-5P
736993-88-7P 736993-90-1P 736993-92-3P
736993-94-5P 736993-96-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)
RN 736993-82-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, N-butyl-7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 736993-84-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-N-[2-(4-fluorophenyl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 736993-86-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 736993-88-7 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-N-(6-methoxy-3-pyridinyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 736993-90-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 736993-92-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-N,2-dimethyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 736993-94-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-

chlorophenyl)-2-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 736993-96-7 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-N-(2,2-difluoropropyl)-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:646209 CAPLUS
DN 142:211382
TI Novel Diamino Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A2a Receptor Antagonists
AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Kumaravel, Gnanasambandam; Smits, Glenn; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Grant, Donna; Hetu, Gregg; Petter, Russell C.
CS Department of Medicinal Chemistry, Biogen Idec Inc., Cambridge, MA, 02142, USA
SO Journal of Medicinal Chemistry (2005), 48(6), 2009-2018
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:211382
IT 745072-67-7P 745072-73-5P 745072-74-6P
745072-77-9P 745072-78-0P 745072-80-4P
745072-82-6P 745072-88-2P 745072-94-0P
745072-97-3P 745073-02-3P 745073-05-6P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists)
RN 745072-67-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-73-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 745072-74-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 745072-77-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3S)-1-[(5-methyl-3-isoxazolyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-78-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-80-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-82-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-88-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-94-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-97-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(2,4,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-02-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-05-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 745072-68-8P 745072-69-9P 745072-70-2P
745072-71-3P 745072-75-7P 745072-76-8P
745072-79-1P 745072-81-5P 745072-83-7P
745072-84-8P 745072-85-9P 745072-86-0P
745072-87-1P 745072-89-3P 745072-90-6P
745072-91-7P 745072-92-8P 745072-93-9P
745072-95-1P 745072-96-2P 745072-98-4P
745072-99-5P 745073-00-1P 745073-01-2P
745073-03-4P 745073-04-5P 745073-06-7P
745072-07-8P 745073-08-9P 745073-09-0P
745073-10-3P 745073-11-4P 745073-12-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists)

RN 745072-68-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-69-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[3-[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 745072-70-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2,2-dimethyl-3-[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 745072-71-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[(1S,2S)-2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-75-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 745072-76-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 745072-79-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2S)-

1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-81-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-83-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-84-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(4-

chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-85-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-86-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-87-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-89-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-90-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-91-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,4-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-92-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-93-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3-chloro-2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-95-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(2,4,5-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-96-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-[(2,3,6-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-98-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-99-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-00-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-01-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-03-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(3-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-04-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-06-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-07-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(2-furanylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-08-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(5-chloro-2-furanyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-09-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-10-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-11-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[(2R)-1-(2-benzofuranylmethyl)-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-12-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[(2R)-1-(2-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 139180-30-6, ZM-241385 745072-66-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 745072-66-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



IT 745073-14-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists)
RN 745073-14-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-pyrrolidinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 745073-13-6
CMF C13 H16 N8 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:604078 CAPLUS
DN 141:168324
TI Striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats
AU Golembiowska, Krystyna; Dziubina, Anna
CS Institute of Pharmacology, Polish Academy of Sciences, Krakow, 31343, Pol.
SO Neuropharmacology (2004), 47(3), 414-426
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:570030 CAPLUS
DN 141:99661
TI Identification of compounds suitable as agonists and/or antagonists of adenosine A2A receptor coupled to specific G proteins, and use of identified compounds in treatment of various disorders in mammals
IN Fredholm, Bertil B.; Kull, Bjoern
PA Actar Ab, Swed.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058974	A1	20040715	WO 2003-SE2086	20031229
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003291608	A1	20040722	AU 2003-291608	20031229
PRAI US 2002-436480P	P	20021227		
WO 2003-SE2086	W	20031229		

IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A2A receptor antagonist ZM 241385 has poorer selectivity towards Golf verses Gs)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:551512 CAPLUS
DN 141:99601
TI Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum
AU Tebano, Maria Teresa; Pintor, Annita; Frank, Claudio; Domenici, Maria Rosaria; Martire, Alberto; Pepponi, Rita; Potenza, Rosa Luisa; Grieco, Rosa; Popoli, Patrizia
CS Department of Pharmacology, Istituto Superiore di Sanita, Rome, Italy
SO Journal of Neuroscience Research (2004), 77(1), 100-107
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuroprotective potential of A2A receptor antagonists against excitotoxicity in rat striatum and role of presynaptic mechanisms)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:509593 CAPLUS
DN 141:405812
TI A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis
AU Sullivan, Gail W.; Fang, Guodong; Linden, Joel; Scheld, W. Michael
CS Department of Internal Medicine, University of Virginia, Charlottesville, VA, USA
SO Journal of Infectious Diseases (2004), 189(10), 1897-1904
CODEN: JIDIAQ; ISSN: 0022-1899
PB University of Chicago Press
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective A2A AR antagonist ZM241385 did not significantly increase mortality in absence of AR agonist and reduced protective effect of ATL146e, IB-MECA in mouse model of endotoxemia and sepsis)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:353631 CAPLUS
DN 141:1715
TI Direct interaction of adenosine with the TRPV1 channel protein
AU Puntambekar, Preeti; Van Buren, Jeremy; Raisinghani, Manish; Premkumar, Louis S.; Ramkumar, Vickram
CS Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, 62794-9629, USA
SO Journal of Neuroscience (2004), 24(14), 3663-3671
CODEN: JNRSDS; ISSN: 0270-6474
PB Society for Neuroscience
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(direct interaction of adenosine with TRPV1 channel protein as evaluated in HEK293 cells, fetal rat dorsal root ganglia cultures and Xenopus oocytes)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:213189 CAPLUS
DN 141:17782
TI The mouse brain adenosine A1 receptor: functional expression and pharmacology
AU Wittendorp, Maria C.; Von Frijtag Drabbe Kunzel, Jacobien; IJzerman, Adriaan P.; Boddeke, Hendrikus W. G. M.; Biber, Knut
CS Department of Medical Physiology, University of Groningen, Groningen, 9713 AV, Neth.
SO European Journal of Pharmacology (2004), 487(1-3), 73-79
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mouse brain adenosine A1 receptor in relation to mol. cloning, functional expression and pharmacol.)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 46 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:188255 CAPLUS
DN 141:119341
TI Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors
AU Sihver, W.; Bier, D.; Holschbach, M. H.; Schulze, A.; Wutz, W.; Olsson, R. A.; Coenen, H. H.
CS Institut fur Nuklearchemie, Forschungszentrum Julich GmbH, Julich, 52425, Germany
SO Nuclear Medicine and Biology (2004), 31(2), 173-177
CODEN: NMBIEO; ISSN: 0969-8051
PB Elsevier Science Inc.
DT Journal
LA English
IT 316789-88-5P 724457-46-9P 724457-47-0P
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and binding to brain A2A adenosine receptor)
RN 316789-88-5 CAPLUS
CN Phen-2-t-ol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 724457-46-9 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-(iodo-131I)- (9CI) (CA INDEX NAME)



RN 724457-47-0 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2,6-di(iodo-131I)- (9CI) (CA INDEX NAME)



IT 724457-48-1P 724457-49-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and radioiodination of)
RN 724457-48-1 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-iodo- (9CI) (CA INDEX NAME)



RN 724457-49-2 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2,6-diiodo- (9CI) (CA INDEX NAME)



IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tritiated and radioiodinated ZM241,385 binding by brain A2A adenosine receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:119973 CAPLUS
DN 141:236035
TI Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2A Receptor Agonist: Role of A2A Receptor and Erk1/2
AU Kis, Adrienn; Baxter, Gary F.; Yellon, Derek M.
CS Hatter Institute, UCL Hospitals and Medical School, London, UK
SO Cardiovascular Drugs and Therapy (2003), 17(5/6), 415-425
CODEN: CDTHET; ISSN: 0920-3206
PB Kluwer Academic Publishers
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective adenosine A2A antagonist ZM241385 caused raise in blood pressure, completely blocked depressor action of AMP579 providing confirmation of blockade of A2A receptor activation by ZM241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 48 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:51829 CAPLUS
DN 140:314424
TI Synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor antagonists
AU Alanine, Alexander; Anselm, Lilli; Steward, Lucinda; Thomi, Stefan; Vifian, Walter; Groaning, Michael D.
CS Lead Generation, Discovery Chemistry, Pharmaceuticals Division, F. Hoffmann-La Roche AG, Basel, CH 4070, Switz.
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(3), 817-821
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:314424
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 49 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:2642 CAPLUS
DN 140:70996
TI Enhancing treatment of MDR cancer with adenosine A3 antagonists
IN Borea, Pier Andrea; Baraldi, Pier Giovanni; Chen, Shih-Fong; Leung, Edward
PA King Pharmaceuticals Research & Development, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000237	A2	20031231	WO 2003-US20118	20030624
	WO 2004000237	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464539	AA	20031231	CA 2003-2464539	20030624
	AU 2003245693	A1	20040106	AU 2003-245693	20030624
	US 2004067932	A1	20040408	US 2003-603406	20030624
	BR 2003005106	A	20040928	BR 2003-5106	20030624
	EP 1515719	A2	20050323	EP 2003-739312	20030624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005530858	T2	20051013	JP 2004-530977	20030624
PRAI	US 2002-391009P	P	20020624		
	US 2002-394395P	P	20020708		
	WO 2003-US20118	W	20030624		

OS MARPAT 140:70996
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A3 antagonists for enhancing treatment of MDR cancer)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 50 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:2631 CAPLUS
DN 140:70994
TI Enhancing treatment of MDR cancer with adenosine A3 antagonists
IN Borea, Pier Andrea; Baraldi, Pier Giovanni; Chen, Shih-Fong; Leung, Edward
PA King Pharmaceuticals Research & Development, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000224	A2	20031231	WO 2003-US19687	20030620
	WO 2004000224	A3	20040408		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003251595	A1	20040106	AU 2003-251595	20030620
	US 2005119289	A1	20050602	US 2003-600116	20030620
	ZA 2004001450	A	20050310	ZA 2004-1450	20040224
PRAI	US 2002-391009P	P	20020624		
	WO 2003-US19687	W	20030620		

OS MARPAT 140:70994
IT 139180-30-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A3 antagonists for enhancing treatment of MDR cancer)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:924144 CAPLUS
DN 140:210302
TI Modulation of A2A Adenosine Receptors and Associated Gαs Proteins by ZM 241385 Treatment of Porcine Coronary Artery
AU Rekik, Moez; Mustafa, Jamal S.
CS Department of Pharmacology, Brody School of Medicine, East Carolina University, Greenville, NC, USA
SO Journal of Cardiovascular Pharmacology (2003), 42(6), 736-744
CODEN: JCPCDT; ISSN: 0160-2446
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulation of A2A adenosine receptors and associated Gαs proteins by ZM 241385 treatment of porcine coronary artery)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 52 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:796432 CAPLUS
DN 139:302061
TI Synergy of dopamine D2 and adenosine A2 receptors activates protein kinase A (PKA) signaling via β/γ dimers, and use in the treatment of drug abuse and drug withdrawal
IN Gordon, Adrienne S.; Diamond, Ivan F.; Yao, Lina
PA The Regents of the University of California, USA
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082211	A2	20031009	WO 2003-US9629	20030327
	WO 2003082211	A3	20041216		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003241281	A1	20031013	AU 2003-241281	20030327
PRAI	US 2002-368417P	P	20020327		
	WO 2003-US9629	W	20030327		

IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergy of dopamine D2 and adenosine A2 receptors activates protein kinase A signaling via β/γ dimers, and use in treatment of drug abuse and drug withdrawal)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 53 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:737760 CAPLUS
DN 139:261327
TI Preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections
IN Gudmundsson, Kristjan; Johns, Brian A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003076441	A1	20030918	WO 2003-US5704	20030224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217712	A1	20030922	AU 2003-217712	20030224
EP 1485385	A1	20041215	EP 2003-713672	20030224
EP 1485385	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005124616	A1	20050609	US 2003-505386	20030224
JP 2005525382	T2	20050825	JP 2003-574658	20030224
AT 302203	E	20050915	AT 2003-713672	20030224
ES 2245772	T3	20060116	ES 2003-3713672	20030224
PRAI US 2002-362298P	P	20020307		
WO 2003-US5704	W	20030224		

OS MARPAT 139:261327
IT 601521-27-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections)
RN 601521-27-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N,N'-dicyclopentyl-8-[2-(cyclopentylamino)-4-pyridinyl]-7-phenyl- (9CI) (CA INDEX NAME)



11/449,613

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 54 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:690022 CAPLUS
DN 140:174918
TI Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog
AU Fozard, John R.; Baur, Francois; Wolber, Cedric
CS Research Department, Novartis Pharma AG, Basel, CH-4002, Switz.
SO European Journal of Pharmacology (2003), 475(1-3), 79-84
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(antagonist pharmacol. of adenosine A2B receptors from rat, guinea pig and dog)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 55 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:519332 CAPLUS
DN 139:390718
TI Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats
AU Villanueva-Toledo, Jairo; Moo-Puc, Rosa E.; Gongora-Alfaro, Jose L.
CS "Dr. Hideyo Noguchi", Centro de Investigaciones Regionales, Laboratorio de Neurofisiologia, Universidad Autonoma de Yucatan, Merida, Yucatan, 97000, Mex.
SO Neuroscience Letters (2003), 346(1,2), 1-4
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 56 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:472597 CAPLUS
DN 139:47145
TI Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
IN Sitkovsky, Michail V.; Ohta, Akio
PA The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services, USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003050241	A2	20030619	WO 2002-US36829	20021114
	WO 2003050241	A3	20040129		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2470104	AA	20030619	CA 2002-2470104	20021114
	AU 2002356962	A1	20030623	AU 2002-356962	20021114
	EP 1465634	A2	20041013	EP 2002-804693	20021114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005516917	T2	20050609	JP 2003-551263	20021114
	US 2005220799	A1	20051006	US 2004-498416	20040610
PRAI	US 2001-340772P	P	20011212		
	US 2001-342585P	P	20011219		
	WO 2002-US36829	W	20021114		

IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 57 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:376384 CAPLUS
DN 138:396214
TI Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IN Liang, Bruce T.; Jacobson, Kenneth A.
PA USA
SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. 6,211,165.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003092668	A1	20030515	US 2001-800274	20010305
	US 6586413	B2	20030701		
	US 6211165	B1	20010403	US 1999-423129	19991105
PRAI	US 1999-423129	A2	19991105		
	US 1997-46030P	P	19970509		
	US 1997-61716P	P	19971010		
	WO 1998-US9031	W	19980508		

IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine receptor agonists and antagonists for reducing cardiac ischemic injury)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 58 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:330660 CAPLUS
DN 139:270317
TI Binding of HTLV-1 virions to T cells occurs by a temperature and calcium-dependent process and is blocked by certain type 2 adenosine receptor antagonists
AU Hague, Bishop F.; Zhao, Tong Mao; Kindt, Thomas J.
CS National Institute of Allergy and Infectious Diseases, Molecular and Cellular Immunogenetics Section, National Institutes of Health, Bethesda, MD, 20892, USA
SO Virus Research (2003), 93(1), 31-39
CODEN: VIREDF; ISSN: 0168-1702
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, Zm241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HTLV-1 virions binding to T cells is temperature and calcium-dependent and is blocked by adenosine antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 59 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:793451 CAPLUS
DN 137:289033
TI Adenosine A2A receptor antagonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease
IN Peters, Dan; Ronn, Lars Christian; Nielsen, Karin Sandager
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080957	A1	20021017	WO 2002-DK228	20020404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2440196	AA	20021017	CA 2002-2440196	20020404
	EP 1379269	A1	20040114	EP 2002-759761	20020404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529916	T2	20040930	JP 2002-578996	20020404
	US 2004097540	A1	20040520	US 2003-473809	20031002
PRAI	DK 2001-583	A	20010409		
	WO 2002-DK228	W	20020404		

IT 139180-30-6, ZM-241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonists combined with neurotrophic compds. in treatment of Parkinson's disease)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 60 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:787957 CAPLUS
DN 138:148014
TI Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385
AU Demet, Edward M.; Chicz-Demet, Aleksandra
CS Mental Health Care Group, Veterans Affairs Medical Center (116A), Long Beach, CA, 90822, USA
SO Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 366(5), 478-481
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 61 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:616371 CAPLUS
DN 137:150232
TI Method and compositions using A2A adenosine receptor agonists for treating the inflammatory response
IN Linden, Joel M.; Rieger, Jayson M.; Sullivan, Gail W.; MacDonald, Timothy L.
PA University of Virginia Patent Foundation, USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002111327	A1	20020815	US 2002-41776	20020107
US 6670334	B2	20031230		
PRAI US 2001-260059P	P	20010105		

OS MARPAT 137:150232
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor agonists for treating inflammatory response)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 62 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:616265 CAPLUS
DN 137:150259
TI Method for screening molecules that exert a neurotrophic effect through activation of neurotrophin receptors
IN Chao, Moses V.; Lee, Francis S.
PA USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002110837	A1	20020815	US 2001-982095	20011019
PRAI US 2000-255887P	P	20001218		

IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(screening mols. that exert neurotrophic effect through activation of neurotrophin receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 63 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:353649 CAPLUS
DN 136:365554
TI Polymorphic variants of human adenosine 2a receptor associated with diseases and diagnostic and therapeutic methods
IN Dowell, Simon Jeremy; Sheehan, Michael John
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036816	A2	20020510	WO 2001-GB4865	20011102
	WO 2002036816	A3	20030530		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002010761	A5	20020515	AU 2002-10761	20011102
PRAI	GB 2000-26945	A	20001103		
	GB 2000-29577	A	20001202		
	WO 2001-GB4865	W	20011102		

IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study) (as A2a receptor antagonist, in drug screening assays; polymorphic variants of human adenosine 2a receptor associated with diseases and diagnostic and therapeutic methods)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 64 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:290503 CAPLUS
DN 137:179743
TI Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists
AU Behan, W. M. H.; Stone, T. W.
CS Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO British Journal of Pharmacology (2002), 135(6), 1435-1442
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 65 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:276273 CAPLUS
DN 136:273219
TI Diagnosing Huntington's disease and means of treating it
IN Cattabeni, Flaminio Nicola; Cattaneo, Elena; Abbracchio, Mariapia; Varani, Katia; Borea, Pier Andrea
PA Universita' Degli Studi Di Milano, Italy; Universita' Degli Studi Di Ferrara
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002029408	A2	20020411	WO 2001-EP11425	20011003
	WO 2002029408	A3	20021212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT 1318960	B1	20030919	IT 2000-MI2137	20001003
	AU 2002013990	A5	20020415	AU 2002-13990	20011003
	EP 1325335	A2	20030709	EP 2001-982391	20011003
	EP 1325335	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 323287	E	20060415	AT 2001-982391	20011003
	US 2004023312	A1	20040205	US 2003-398499	20030807
PRAI	IT 2000-MI2137	A	20001003		
	WO 2001-EP11425	W	20011003		

IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(diagnosing Huntington's disease and means of treating it)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 66 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:85503 CAPLUS
DN 136:227186
TI Purification and characterization of the human adenosine A2a receptor functionally expressed in Escherichia coli
AU Weiss, H. Markus; Grisshammer, Reinhard
CS MRC Laboratory of Molecular Biology, Cambridge, UK
SO European Journal of Biochemistry (2002), 269(1), 82-92
CODEN: EJBCAI; ISSN: 0014-2956
PB Blackwell Publishing Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(purification and characterization of human adenosine A2a receptor functionally expressed in Escherichia coli)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 67 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:54358 CAPLUS
DN 137:134868
TI Hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: effect of theophylline and ZM 241385
AU Higashi, Hisato; Meno, Joseph R.; Marwaha, Amitoj S.; Winn, H. Richard
CS Department of Neurological Surgery, University of Washington, Seattle, WA, USA
SO Journal of Neurosurgery (2002), 96(1), 117-126
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: effect of theophylline and ZM 241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 68 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:38775 CAPLUS
DN 137:103775
TI Role of adenosine receptors in neuroprotective effect during global cerebral ischemia
AU Kulinsky, V. I.; Minakina, L. N.; Usov, L. A.
CS Department of Biochemistry, Irkutsk Medical University, Russia
SO Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2001), 131(5), 454-456
CODEN: BEXBAN; ISSN: 0007-4888
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of adenosine receptors in neuroprotective effect during global cerebral ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 69 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:915602 CAPLUS
DN 136:303408
TI New developments in A1 and A2 adenosine receptor antagonists
AU Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.; Michalak, B.; Miller, C. E.; Schumacher, B.; Karolak-Wojciechowska, J.; Duddeck, H.; Rockitt, S.; Wartchow, R.
CS IUPAC Commission, Medical College, Department of Chemical Technology of Drugs, Jagiellonian University, Krakow, PL 30-688, Pol.
SO Pure and Applied Chemistry (2001), 73(9), 1411-1420
CODEN: PACHAS; ISSN: 0033-4545
PB International Union of Pure and Applied Chemistry
DT Journal; General Review
LA English
IT 139180-30-6P, Zm 241385
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(new developments in A1 and A2 adenosine receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 70 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:864519 CAPLUS
DN 136:129190
TI Solubilization and immunoprecipitation of rat striatal adenosine A2A receptors
AU Harvey, Victoria; Jones, Julie; Misra, Anil; Knight, Antony R.; Quirk, Kathleen
CS Department of Molecular Pharmacology, Vernalis Research Ltd., Winnersh, Wokingham, RG41 5UA, UK
SO European Journal of Pharmacology (2001), 431(2), 171-177
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(adenosine A2A receptors of rat striatum solubilization and immunopptn.)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 71 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:749297 CAPLUS
DN 136:79626
TI Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia
AU Richter, Angelika; Hamann, Melanie
CS Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine Hannover, Hannover, 30559, Germany
SO British Journal of Pharmacology (2001), 134(2), 343-352
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 72 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:730232 CAPLUS
DN 136:85799
TI The design and synthesis of structurally related mercaptopurine analogs: reaction of dimethyl N-cyanodithioiminocarbonate with 5-aminopyrazoles
AU Elgemeie, Galal H.; El-Ezbawy, Samia R.; El-Aziz, Hany A.
CS Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt
SO Synthetic Communications (2001), 31(22), 3453-3458
CODEN: SYNCAV; ISSN: 0039-7911
PB Marcel Dekker, Inc.
DT Journal
LA English
OS CASREACT 136:85799
IT 387335-13-9P 387335-14-0P 387335-15-1P
387335-16-2P 387335-17-3P 387335-18-4P
387335-19-5P 387335-20-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(mercaptopurine analogs via reaction of di-Me N-cyanodithioiminocarbonate with 5-aminopyrazoles)
RN 387335-13-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4(1H)-one, 2-amino-7-phenyl-, hydrazone (9CI) (CA INDEX NAME)



RN 387335-14-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4(1H)-one, 2-amino-7-(4-methylphenyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 387335-15-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4(1H)-one, 2-amino-7-(4-methoxyphenyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 387335-16-2 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4(1H)-one, 2-amino-7-(4-chlorophenyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 387335-17-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N4,7-diphenyl- (9CI) (CA INDEX NAME)



RN 387335-18-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(4-methylphenyl)-N4-phenyl- (9CI) (CA INDEX NAME)



RN 387335-19-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(4-methoxyphenyl)-N4-phenyl- (9CI) (CA INDEX NAME)



RN 387335-20-8 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(4-chlorophenyl)-N4-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 73 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:688889 CAPLUS
DN 136:48351
TI Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice
AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Bertorelli, Rosalia; Ongini, Ennio; Costentin, Jean; Vaugeois, Jean-Marie
CS UMR 6036 CNRS, IFRMP 23, U.F.R. de Medecine and Pharmacie, Rouen, 76183, Fr.
SO British Journal of Pharmacology (2001), 134(1), 68-77
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonists are potential antidepressants in A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 74 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:597739 CAPLUS
DN 135:162508
TI Adenosine A2a receptor antagonist for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
IN Cronstein, Bruce N.; Chan, Edwin
PA New York University, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058241	A2	20010816	WO 2001-US4341	20010212
	WO 2001058241	C2	20021017		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2398908	AA	20010816	CA 2001-2398908	20010212
	AU 2001038124	A5	20010820	AU 2001-38124	20010212
	US 2002002145	A1	20020103	US 2001-780365	20010212
	US 6555545	B2	20030429		
	JP 2004502640	T2	20040129	JP 2001-557366	20010212
	AU 2006203699	A1	20060921	AU 2006-203699	20060825
PRAI	US 2000-181546P	P	20000210		
	WO 2001-US4341	W	20010212		

IT 139180-30-6, ZM 241385
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 75 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:216425 CAPLUS
DN 135:40644
TI Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists
AU Sullivan, Gail W.; Rieger, Jayson M.; Scheld, W. Michael; Macdonald, Timothy L.; Linden, Joel
CS Department of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
SO British Journal of Pharmacology (2001), 132(5), 1017-1026
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cAMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 76 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:74904 CAPLUS
DN 134:142165
TI [3H]ZM241385-an antagonist radioligand for adenosine A2A receptors in rat brain
AU Alexander, S. P. H.; Millns, P. J.
CS Neuroscience and Pharmacology, School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
SO European Journal of Pharmacology (2001), 411(3), 205-210
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385 316789-88-5
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(ZM 241385 as radioligand for adenosine A2A receptor characterization in rat brain)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 316789-88-5 CAPLUS
CN Phen-2-t-ol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME).



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 77 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:21203 CAPLUS
DN 134:217113
TI Effect of the adenosine A2A-receptors on the brain stability with respect to complete global cerebral ischemia
AU Kulinskii, V. I.; Minakina, L. N.; Usov, L. A.
CS Departments of Biochemistry and Pharmacology, Irkutsk Medical University, Irkutsk, 664003, Russia
SO Eksperimental'naya i Klinicheskaya Farmakologiya (2000), 63(6), 9-11
CODEN: EKFAE9; ISSN: 0869-2092
PB Izdatel'stvo Folium
DT Journal
LA Russian
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effect of the adenosine A2A-receptors on the brain stability with respect to complete global cerebral ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 78 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:893911 CAPLUS
DN 134:51525
TI Why are A2B receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-(1-hexynyl)adenosine
AU Beukers, Margot W.; den Dulk, Hans; Van Tilburg, Erica W.; Brouwer, Jaap; Ijerman, Adriaan P.
CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, Neth.
SO Molecular Pharmacology (2000), 58(6), 1349-1356
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A2B receptors are low-affinity adenosine receptors and mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-substituted adenosines)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 79 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:526436 CAPLUS
DN 133:217854
TI Site-directed mutagenesis studies of human A2A adenosine receptors. Involvement of glu13 and his278 in ligand binding and sodium modulation
AU Gao, Z.-G.; Jiang, Q.; Jacobson, K. A.; Ijzerman, A. P.
CS P.O. Box 9502, Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Leiden University, Leiden, 2300 RA, Neth.
SO Biochemical Pharmacology (2000), 60(5), 661-668
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(site-directed mutagenesis of glu13 and his278 in human A2A adenosine receptor in relation to ligand binding and sodium modulation)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 80 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:480897 CAPLUS
DN 133:346544
TI Further characterization of a CNS adenosine A2a receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake
AU Ishiwata, Kiichi; Ogi, Nobuo; Shimada, Junichi; Nonaka, Hiromi; Tanaka, Akira; Suzuki, Fumio; Senda, Michio
CS Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, 173-0022, Japan
SO Annals of Nuclear Medicine (2000), 14(2), 81-89
CODEN: ANMEEX; ISSN: 0914-7187
PB Japanese Society of Nuclear Medicine
DT Journal
LA English
IT 139180-30-6, ZM 241385 158747-27-4, ZD 9255
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(CNS adenosine A2a receptor ligand [11C]KF18446: blockade of binding in brain by adenosine antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 158747-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 81 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:154677 CAPLUS
DN 132:274243
TI The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A2A adenosine receptor antagonists
AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Costentin, Jean; Vaugeois, Jean-Marie
CS UPRESA 6036 CNRS, U.F.R. de Medecine and Pharmacie, Rouen, 76183, Fr.
SO Psychopharmacology (Berlin) (2000), 148(2), 153-163
CODEN: PSCHDL; ISSN: 0033-3158
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(anxiogenic-like effect of caffeine in mouse is not shared by selective A2A adenosine receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 82 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:97878 CAPLUS
DN 132:260556
TI Effects of P1 and P2 receptor antagonists on β,γ-methyleneATP- and CGS21680-induced cyclic AMP formation in NG108-15 cells
AU Ohkubo, Satoko; Kimura, Junko; Nakanishi, Hironori; Matsuoka, Isao
CS Department of Pharmacology, School of Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan
SO British Journal of Pharmacology (2000), 129(2), 291-298
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ATP-stimulated cAMP formation can be distinguished from A2A receptor agonist-induced by using the several P1 and P2 receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 83 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:85698 CAPLUS
DN 132:220005
TI Antagonism of coronary artery relaxation by adenosine A2A-receptor antagonist ZM241385
AU Hasan, A. Z. M. Arif; Abebe, Worku; Mustafa, S. Jamal
CS Department of Pharmacology, ECU School of Medicine, Greenville, NC, USA
SO Journal of Cardiovascular Pharmacology (2000), 35(2), 322-325
CODEN: JCPCDT; ISSN: 0160-2446
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZM241385 A2A receptor-selective antagonism: functional A2A adenosine receptor in coronary artery)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 84 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:27238 CAPLUS
DN 132:202624
TI Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity
AU De Zwart, Maarten; Vollinga, Roel C.; Beukers, Margot W.; Sleegers, Danielle F.; Von Frijtag Drabbe Kunzel, Jacobien K.; De Groote, Miriam; Ijzerman, Ad P.
CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, 2300 RA, Neth.
SO Drug Development Research (1999), 48(3), 95-103
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139179-78-5, LUF 5453 139179-82-1, LUF 5451
139179-86-5, LUF 5452 139179-88-7, LUF 5461
139180-17-9, LUF 5460 139180-30-6, ZM241385
139180-90-8, LUF 5441 139181-13-8, LUF 5458
260370-68-1, LUF 5478 260370-69-2, LUF 5455
260370-70-5, LUF 5456 260370-71-6, LUF 5457
260370-72-7, LUF 5459 260370-73-8, LUF 5479
260370-74-9, LUF 5462 260370-75-0, LUF 5475
260370-76-1, LUF 5477
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(derivs. of triazolotriazine ZM241385 as potent antagonists for human adenosine A2B receptors with high affinity in relation to structure)
RN 139179-78-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-phenyl- (9CI) (CA INDEX NAME)



RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 139179-86-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 139179-88-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-17-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-90-8 CAPLUS
CN Phenol, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-13-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 260370-68-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 260370-69-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(4-chlorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 260370-70-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(2-chlorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 260370-71-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(3,4-dichlorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 260370-72-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 260370-73-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(diphenylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 260370-74-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 260370-75-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5(1H)-one, 7-amino-2-(2-furanyl)-, phenylhydrazone (9CI) (CA INDEX NAME)



RN 260370-76-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(cyclohexylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 85 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:775949 CAPLUS
DN 132:88584
TI ZM 241385, an adenosine A2A receptor antagonist, inhibits hippocampal A1 receptor responses
AU Lopes, L. V.; Cunha, R. A.; Ribeiro, J. A.
CS Faculty of Medicine, Laboratory of Neurosciences, University of Lisbon, Lisbon, 1649-028, Port.
SO European Journal of Pharmacology (1999), 383(3), 395-398
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(adenosine A2A receptor antagonist ZM 241385 inhibits hippocampal A1 receptor responses)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 86 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:745744 CAPLUS
DN 132:44931
TI Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors
AU Ji, Xiao-Duo; Jacobson, Kenneth A.
CS Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
SO Drug Design and Discovery (1999), 16(3), 217-226
CODEN: DDDIEV; ISSN: 1055-9612
PB Harwood Academic Publishers
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(use of triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 87 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:721665 CAPLUS
DN 132:30682
TI Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischemia in rat hippocampal slices
AU Latini, Serena; Bordoni, Francesca; Corradetti, Renato; Pepeu, Giancarlo; Pedata, Felicita
CS Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, 50139, Italy
SO British Journal of Pharmacology (1999), 128(5), 1035-1044
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(A2A adenosine receptor role in hippocampal synaptic transmission in ischemia: A2A and A1 receptor interaction as possible mechanism of protection against ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) .(CA INDEX NAME)



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 88 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:693087 CAPLUS
DN 132:347
TI Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors
AU Fredholm, Bertil B.; Lindstrom, Karin
CS Department of Physiology and Pharmacology, Section of Molecular Neuropharmacology, Karolinska Institutet, Stockholm, S-171 77, Swed.
SO European Journal of Pharmacology (1999), 380(2/3), 197-202
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(autoradiog. comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 89 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:644568 CAPLUS
DN 131:346931
TI Characterization of human A2B adenosine receptors: radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells
AU Linden, Joel; Thai, Tami; Figler, Heidi; Jin, Xiaowei; Robeva, Anna S.
CS Departments of Internal Medicine Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA
SO Molecular Pharmacology (1999), 56(4), 705-713
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(characterization of human A2B adenosine receptors in relation to radioligand binding, Western blotting and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 90 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:518676 CAPLUS
DN 131:167097
TI Nitric oxide synthase-inhibiting amide derivatives for treatment of septicemia
IN Iwamoto, Takefumi; Yasuda, Tsuneo; Okamura, Takashi; Koji, Yasuo; Shibuya, Naotaka
PA Ohtsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11222435	A2	19990817	JP 1998-24671	19980205
PRAI JP 1998-24671		19980205		

OS MARPAT 131:167097
IT 200292-11-1P 238765-40-7P 238765-41-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitric oxide synthase-inhibiting amide derivs. for treatment of septicemia)
RN 200292-11-1 CAPLUS
CN Benzamide, N-(2-butyl-7-phenylpyrazolo[1,5-a]-1,3,5-triazin-4-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 238765-40-7 CAPLUS
CN Benzamide, N-(2-butyl-7-phenylpyrazolo[1,5-a]-1,3,5-triazin-4-yl)-3-chloro- (9CI) (CA INDEX NAME)



RN 238765-41-8 CAPLUS
CN Benzamide, N-(2-butyl-7-phenylpyrazolo[1,5-a]-1,3,5-triazin-4-yl)-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 91 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:451298 CAPLUS
DN 131:116251
TI Preparation of purine derivatives as adenosine A2 receptor antagonists for the treatment of diabetes
IN Asano, Osamu; Harada, Hitoshi; Hoshino, Yorihisa; Yoshikawa, Seiji; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Nagata, Kaya; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935147	A1	19990715	WO 1998-JP5870	19981224
	W: AU, BR, CA, CN, HU, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 11263789	A2	19990928	JP 1998-363938	19981222
	CA 2315736	AA	19990715	CA 1998-2315736	19981224
	AU 9916885	A1	19990726	AU 1999-16885	19981224
	EP 1054012	A1	20001122	EP 1998-961528	19981224
	EP 1054012	B1	20030611		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	EP 1300147	A1	20030409	EP 2002-29118	19981224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 242775	E	20030615	AT 1998-961528	19981224
	US 6579868	B1	20030617	US 2000-582840	20000705
	US 39112	E	20060530	US 2000-57854	20000705
PRAI	JP 1998-526	A	19980105		
	EP 1998-961528	A3	19981224		
	WO 1998-JP5870	W	19981224		

OS MARPAT 131:116251
IT 139180-30-6P 158747-27-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of purine derivs. as adenosine A2 receptor antagonists for treatment of diabetes)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 158747-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 92 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:292524 CAPLUS
DN 131:96959
TI Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists
AU Baraldi, Pier Giovanni; Borea, Pier Andrea; Bergonzoni, Manuela; Cacciari, Barbara; Ongini, Ennio; Recanatini, Maurizio; Spalluto, Giampiero
CS Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Ferrara, 44100, Italy
SO Drug Development Research (1999), 46(2), 126-133
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139180-30-6P, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(comparative mol. field anal. of selective adenosine receptor A2A antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 93 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:797623 CAPLUS
DN 130:163466
TI Characterization of adenosine receptors evoking excitation of mesenteric afferents in the rat
AU Kirkup, A. J.; Eastwood, C.; Grundy, D.; Chessell, I. P.; Humphrey, P. P. A.
CS Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, UK
SO British Journal of Pharmacology (1998), 125(6), 1352-1360
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(characterization of adenosine receptors evoking excitation of mesenteric afferents in the rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 94 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:792698 CAPLUS
DN 130:261903
TI Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
AU Ongini, E.; Dionisotti, Silvio; Gessi, Stefania; Irenius, E.; Fredholm, Bertil B.
CS San Raffaele Science Park, Schering-Plough Research Institute, Milan, I-20132, Italy
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1999), 359(1), 7-10
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(comparison of CGS 15943 and ZM 241385 and SCH 58261 as antagonists at human adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 95 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:744957 CAPLUS
DN 130:10632
TI Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IN Liang, Bruce T.; Jacobson, Kenneth A.
PA Trustees of the University of Pennsylvania, USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850047	A1	19981112	WO 1998-US9031	19980508
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2289731	AA	19981112	CA 1998-2289731	19980508
	AU 9873677	A1	19981127	AU 1998-73677	19980508
	AU 750322	B2	20020718		
	EP 991414	A1	20000412	EP 1998-920958	19980508
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6211165	B1	20010403	US 1999-423129	19991105
PRAI	US 1997-46030P	P	19970509		
	US 1997-61716P	P	19971010		
	WO 1998-US9031	W	19980508		

IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for reducing ischemic injury of heart by administering adenosine receptor agonists and antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 96 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:618821 CAPLUS
DN 129:225729
TI Methods and compositions for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
IN Liang, Bruce T.; Jacobson, Kenneth A.
PA Trustees of the University of Pennsylvania, USA; National Institute of Health
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9839008	A1	19980911	WO 1998-US4340	19980306
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5859019	A	19990112	US 1997-813787	19970307
	CA 2283449	AA	19980911	CA 1998-2283449	19980306
	AU 9863462	A1	19980922	AU 1998-63462	19980306
	AU 745534	B2	20020321		
	EP 1021187	A1	20000726	EP 1998-907720	19980306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-813787	A	19970307		
	WO 1998-US4340	W	19980306		

IT 139180-30-6, ZMZ 41385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 97 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:466874 CAPLUS
DN 129:211560
TI Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist
AU Jones, P. A.; Smith, R. A.; Stone, T. W.
CS Laboratory of Human Anatomy, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO Brain Research (1998), 800(2), 328-335
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(protection against hippocampal kainate excitotoxicity by intracerebral administration of adenosine A2A receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 98 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:431231 CAPLUS
DN 129:170833
TI Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors
AU Varani, K.; Cacciari, B.; Baraldi, P. G.; Dionisotti, S.; Ongini, E.; Borea, P. A.
CS Dip. Med. Clin. Sperimentale-Sezione Farmacologia, Univ. Studi Ferrara, Ferrara, 44100, Italy
SO Life Sciences (1998), 63(5), PL81-PL87
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier Science Inc.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 99 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:274309 CAPLUS
DN 129:23325
TI Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists
AU Jones, P. A.; Smith, R. A.; Stone, T. W.
CS Division of Neuroscience and Biomedical Systems, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO Neuroscience (Oxford) (1998), 85(1), 229-237
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 100 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:1479 CAPLUS
DN 128:61529
TI Preparation and formulation of amide derivatives as pharmaceuticals
IN Okamura, Takashi; Shoji, Yasuo; Shibutani, Tadao; Yasuda, Tsuneo; Iwamoto, Takeshi
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9746560	A1	19971211	WO 1997-JP1875	19970602
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2257222	AA	19971211	CA 1997-2257222	19970602
	CA 2257222	C	20020820		
	AU 9729778	A1	19980105	AU 1997-29778	19970602
	AU 716633	B2	20000302		
	EP 915093	A1	19990512	EP 1997-924299	19970602
	EP 915093	B1	20021127		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1221419	A	19990630	CN 1997-195345	19970602
	CN 1066448	B	20010530		
	AT 228518	E	20021215	AT 1997-924299	19970602
	TW 470736	B	20020101	TW 1997-86107762	19970606
	US 6166016	A	20001226	US 1998-194727	19981202
	KR 2000016395	A	20000325	KR 1998-709969	19981205
PRAI	JP 1996-144099	A	19960606		
	JP 1997-73116	A	19970326		
	WO 1997-JP1875	W	19970602		

OS MARPAT 128:61529
IT 200292-11-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide derivs. as pharmaceuticals)
RN 200292-11-1 CAPLUS
CN Benzamide, N-(2-butyl-7-phenylpyrazolo[1,5-a]-1,3,5-triazin-4-yl)-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 101 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:801233 CAPLUS
DN 128:124022
TI Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery
AU Prentice, D. J.; Payne, S. L.; Hourani, S. M. O.
CS School of Biological Sciences, University of Surrey, Surrey, GU2 5XH, UK
SO British Journal of Pharmacology (1997), 122(7), 1509-1515
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(activation by adenosine receptor agonists causes relaxation in mesenteric arteries)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 102 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:801204 CAPLUS
DN 128:123731
TI ZM241385 is an antagonist of the facilitatory responses produced by the A2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus
AU Cunha, Rodrigo A.; Constantino, M. Dolores; Ribeiro, J. Alexandre
CS Department of Chemistry & Biochemistry, Facility of Sciences, University of Lisbon, Lisbon, 1700, Port.
SO British Journal of Pharmacology (1997), 122(7), 1279-1284
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ZM241385 antagonism of responses produced by A2A adenosine receptor agonists CGS21680 and HENECA in hippocampus)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 103 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:704675 CAPLUS
DN 127:343393
TI Myocardial adenosine A2a receptor imaging of rabbit by PET with [11C]KF17837
AU Ishiwata, Kiichi; Sakiyama, Yojiro; Sakiyama, Takayo; Shimada, Junichi; Toyama, Hinako; Oda, Keiichi; Suzuki, Fumio; Senda, Michio
CS Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Itabashi, 173, Japan
SO Annals of Nuclear Medicine (1997), 11(3), 219-225
CODEN: ANMEEX; ISSN: 0914-7187
PB Japanese Society of Nuclear Medicine
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(myocardial adenosine A2a receptor imaging by PET with [11C]KF17837)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 104 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:646525 CAPLUS
DN 127:326459
TI Relaxation of the ovine isolated iris sphincter by adenosine receptor agonists: Lack of effect of adenosine A1 and A2 receptor antagonists
AU Hourani, Susanna M. O.; Smith, Neil C.; Nettell, Julia J.; Hall, Judith M.
CS School of Biological Sciences, University of Surrey, Guildford Surrey, GU2 SXH, UK
SO European Journal of Pharmacology (1997), 334(1), 95-98
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(relaxation of the ovine isolated iris sphincter by adenosine receptor agonists and lack of effect of adenosine A1 and A2 receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 105 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:481385 CAPLUS
DN 125:158440
TI Pharmacodynamics of ZM 241385, a potent A2a adenosine receptor antagonist, after enteric administration in rat, cat and dog 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) is currently the most selective for the A2a adenosine receptor antagonist.
AU Poucher, S. M.; keddie, J. R.; Brooks, R.; Shaw, G. R.; McKillop, D.
CS Cardiovascular and Metabolism Department, Zeneca Pharmaceuticals, Macclesfield, SK10 5TG, UK
SO Journal of Pharmacy and Pharmacology (1996), 48(6), 601-606
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pharmacodynamics of potent A2a adenosine receptor antagonist ZM 241385 after enteric administration in rat and cat and dog in relation to role of A2a adenosine receptors in action of adenosine)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 106 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:312987 CAPLUS
DN 125:49785
TI In vivo characterization of ZM 241385, a selective adenosine A2A receptor antagonist
AU Keddie, John R.; Poucher, Simon M.; Shaw, Graham R.; Brooks, Robert; Collis, Michael G.
CS Cardiovascular and Metabolism Department, Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
SO European Journal of Pharmacology (1996), 301(1-3), 107-113
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(selective adenosine A2A receptor antagonist ZM 241385 characterization)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 107 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:27287 CAPLUS
DN 124:76661
TI 125I-4(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor
AU Palmer, Timothy M.; Poucher, Simon M.; Jacobson, Kenneth A.; Stiles, Gary L.
CS Dep. of Medicine and Pharmacology, Duke University Medical Center, Durham, NC, 27710, USA
SO Molecular Pharmacology (1995), 48(6), 970-4
CODEN: MOPMA3; ISSN: 0026-895X
PB Williams & Wilkins
DT Journal
LA English
IT 139180-30-6P, ZM 241385
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(125I-ZM 241385 preparation and selective detection of adenosine A2a receptor in bovine striatum)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



IT 139180-30-6DP, ZM 241385, iodo derivs., iodine-125 labeled
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(125I-ZM 241385 preparation and selective detection of adenosine A2a receptor in bovine striatum)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 108 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:725707 CAPLUS
DN 123:187737
TI The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist
AU Poucher, S. M.; Keddie, J. R.; Singh, P.; Stoggall, S. M.; Caulkett, P. W. R.; Jones, G.; Collis, M. G.
CS Cardiovascular and Metabolism Dep., ZENECA Pharmaceuticals, Macclesfield, SK10 4TG, UK
SO British Journal of Pharmacology (1995), 115(6), 1096-102
CODEN: BJPCBM; ISSN: 0007-1188
PB Macmillan Scientific & Medical Division
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro pharmacol. of ZM 241385, a potent, non-xanthine, A2a selective adenosine receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 109 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:563495 CAPLUS
DN 122:299088
TI Depression remedy
IN Suzuki, Fumio; Koike, Nobuaki; Shimada, Junichi; Kitamura, Shigeto; Ichikawa, Shunji; Nakamura, Joji; Shiozaki, Shizuo
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9507282	A1	19950316	WO 1994-JP1455	19940902
	W: AU, CA, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2148502	AA	19950316	CA 1994-2148502	19940902
	AU 9475467	A1	19950327	AU 1994-75467	19940902
	EP 667349	A1	19950816	EP 1994-925620	19940902
	EP 667349	B1	20010124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 198890	E	20010215	AT 1994-925620	19940902
	ES 2156901	T3	20010801	ES 1994-925620	19940902
	US 5789407	A	19980804	US 1995-424397	19950425
PRAI	JP 1993-221431	A	19930906		
	WO 1994-JP1455	W	19940902		

OS MARPAT 122:299088
IT 139179-78-5P 139179-82-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antidepressant activity and formulations of triazine derivs.)
RN 139179-78-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-phenyl- (9CI) (CA INDEX NAME)



RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 110 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:517839 CAPLUS
DN 123:228139
TI Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]traizolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions
AU Caulkett, Peter W. R.; Jones, Geraint; McPartlin, Mary; Renshaw, Nigel D.; Stewart, Sarah K.; Wright, Brian
CS Zeneca Pharmaceuticals, Macclesfield, SK10 4TG, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1995), (7), 801-8
CODEN: JCPRB4; ISSN: 0300-922X
PB Royal Society of Chemistry
DT Journal
LA English
IT 168211-35-6P 168211-36-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of adenine isosteres)
RN 168211-35-6 CAPLUS
CN Phenol, 4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 168211-36-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N7-propyl- (9CI) (CA INDEX NAME)



L4 ANSWER 111 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:444109 CAPLUS
DN 122:214109
TI Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazines and analogs as adenosine antagonists
IN Rodney, Peter W.; Jones, Geraint; Collis, Michael G.; Poucher, Simon M.
PA UK
SO U.S., 31 pp. Cont.-in-part of U.S. 5,270,311.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5356894	A	19941018	US 1993-94572	19930721
	US 5270311	A	19931214	US 1991-708265	19910528
	PL 167014	B1	19950731	PL 1991-290445	19910528
	CN 1056879	A	19911211	CN 1991-103744	19910529
	ZA 9104094	A	19920226	ZA 1991-4094	19910529
PRAI	GB 1990-11913	A	19900529		
	GB 1990-11914	A	19900529		
	GB 1991-1379	A	19910122		
	GB 1991-1380	A	19910122		
	GB 1991-4125	A	19910227		
	US 1991-708265	A2	19910528		
	GB 1992-26735	A	19921222		

OS MARPAT 122:214109
IT 139181-08-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolotriazines and analogs as adenosine antagonists)
RN 139181-08-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



IT 139179-55-8P 139179-77-4P 139179-78-5P
139179-79-6P 139179-82-1P 139179-83-2P
139179-84-3P 139179-85-4P 139179-86-5P
139179-87-6P 139179-88-7P 139179-89-8P
139179-90-1P 139179-91-2P 139180-03-3P
139180-04-4P 139180-12-4P 139180-13-5P
139180-15-7P 139180-16-8P 139180-17-9P
139180-18-0P 139180-19-1P 139180-20-4P
139180-21-5P 139180-22-6P 139180-23-7P
139180-24-8P 139180-25-9P 139180-26-0P
139180-27-1P 139180-28-2P 139180-29-3P
139180-30-6P 139180-31-7P 139180-65-7P
139180-67-9P 139180-82-8P 139180-83-9P
139180-84-0P 139180-85-1P 139180-86-2P
139180-87-3P 139180-88-4P 139180-90-8P

139180-96-4P 139180-97-5P 139180-98-6P
139180-99-7P 139181-07-0P 139181-09-2P
139181-10-5P 139181-11-6P 139181-12-7P
139181-13-8P 139181-17-2P 139181-20-7P
139181-21-8P 139181-25-2P 139211-51-1P
139211-52-2P 146229-55-2P 158747-27-4P
161792-99-0P 161793-00-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolotriazines and analogs as adenosine antagonists)

RN 139179-55-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-propyl- (9CI) (CA INDEX NAME)



RN 139179-77-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139179-78-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-phenyl- (9CI) (CA INDEX NAME)



RN 139179-79-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-2-propenyl- (9CI) (CA INDEX NAME)



RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 139179-83-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-butyl-2-(2-furanyl)-(9CI) (CA INDEX NAME)



RN 139179-84-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-ethyl-2-(2-furanyl)-(9CI) (CA INDEX NAME)



RN 139179-85-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 139179-86-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 139179-87-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 139179-88-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139179-89-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 139179-90-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5,N5-dimethyl- (9CI) (CA INDEX NAME)



RN 139179-91-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-03-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-04-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(5-chloro-2-furanyl)-N5-cyclohexyl- (9CI) (CA INDEX NAME)



RN 139180-12-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 139180-13-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-propyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 139180-15-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-16-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-pentyl- (9CI) (CA INDEX NAME)



RN 139180-17-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-18-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-(4-chlorophenyl)ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-19-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-bicyclo[2.2.1]hept-2-yl-2-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139180-20-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 139180-21-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(2-fluorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-22-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139180-23-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(1,3-benzodioxol-5-ylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-24-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 139180-25-9 CAPLUS
CN Benzeneacetamide, N-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 139180-26-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 139180-27-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 139180-28-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclopentyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-29-3 CAPLUS
CN Acetic acid, [4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-31-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)



RN 139180-65-7 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(5-methyl-2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-67-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-propyl- (9CI) (CA INDEX NAME)



RN 139180-82-8 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-bicyclo[2.2.1]hept-2-yl-7-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139180-83-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-cyclohexyl-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-84-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-phenyl- (9CI) (CA INDEX NAME)



RN 139180-85-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-[2-(dimethylamino)ethyl]-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-86-2 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-87-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(1-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-88-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-90-8 CAPLUS
CN Phenol, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-96-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 139180-97-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-(cyclopropylmethyl)-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-98-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-99-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)



RN 139181-07-0 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(3-methyl-5-isoxazolyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-09-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-10-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 139181-11-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 139181-12-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-13-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-17-2 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 139181-20-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-21-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(2-ethoxyphenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139181-25-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(3-fluorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139211-51-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(5-methyl-2-furanyl)-N5-propyl- (9CI) (CA INDEX NAME)



RN 139211-52-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(cyclopropylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146229-55-2 CAPLUS
CN Phenol, 2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 158747-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 161792-99-0 CAPLUS
CN Phenol, 4-[2-[[2-(2-furanyl)-7-(methylamino)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 161793-00-6 CAPLUS
CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 112 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:680678 CAPLUS
DN 121:280678
TI Preparation of azole derivatives as adenosine antagonists
IN Jones, Geraint
PA Zeneca Ltd., UK
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414812	A1	19940707	WO 1993-GB2525	19931210
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9309045	A	19940622	ZA 1993-9045	19931202
	AU 9456564	A1	19940719	AU 1994-56564	19931210
	CN 1093708	A	19941019	CN 1993-121279	19931222
PRAI	GB 1992-26735	A	19921222		
	WO 1993-GB2525	W	19931210		

OS MARPAT 121:280678
IT 158747-27-4P 158747-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)
RN 158747-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 158747-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 113 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:580833 CAPLUS
DN 119:180833
TI Preparation of furyltriazolotriazines as adenosine antagonists
IN Jones, Geraint; James, Roger; Hargreaves, Rodney Brian
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 544443	A1	19930602	EP 1992-310542	19921119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2082462	AA	19930526	CA 1992-2082462	19921109
	US 5380714	A	19950110	US 1992-979549	19921120
	JP 05222045	A2	19930831	JP 1992-315384	19921125
PRAI	GB 1991-25002	A	19911125		

OS MARPAT 119:180833
IT 150221-57-1P 150221-58-2P 150221-59-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)
RN 150221-57-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 150221-58-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[3-(dimethylamino)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 150221-59-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[4-(dimethylamino)butyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 114 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:560324 CAPLUS
DN 119:160324
TI Preparation of triazolo[1,5-a]-1,3,5-triazines as adenosine antagonists
IN Hutton, Jonathan
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 544444	A1	19930602	EP 1992-310543	19921119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	ZA 9208450	A	19930525	ZA 1992-8450	19921102
	AU 9228126	A1	19930527	AU 1992-28126	19921104
	AU 656432	B2	19950202		
	CA 2082332	AA	19930526	CA 1992-2082332	19921106
	HU 67756	A2	19950428	HU 1992-3531	19921111
	US 5326869	A	19940705	US 1992-979096	19921120
	NO 9204532	A	19930526	NO 1992-4532	19921124
	JP 05194520	A2	19930803	JP 1992-315387	19921125
	HU 71114	A2	19951128	HU 1994-2757	19940926
	FI 9503146	A	19950622	FI 1995-3146	19950622
PRAI	GB 1991-24968	A	19911125		
	HU 1992-3531	A	19921111		
	FI 1992-5259	A	19921119		

OS CASREACT 119:160324; MARPAT 119:160324
IT 139180-30-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 115 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:428162 CAPLUS
DN 119:28162
TI Preparation of azolo[1,3,5]triazines as adenosine antagonists
IN Caulkett, Peter William Rodney; Jones, Geraint; Poucher, Simon Martin; Collis, Michael George
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 515107	A2	19921125	EP 1992-304409	19920515
	EP 515107	A3	19930113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	US 5290776	A	19940301	US 1992-886798	19920521
	CA 2069455	AA	19921124	CA 1992-2069455	19920522
	NO 9202028	A	19921124	NO 1992-2028	19920522
	AU 9217093	A1	19921126	AU 1992-17093	19920522
	AU 654010	B2	19941020		
	ZA 9203767	A	19930428	ZA 1992-3767	19920522
	HU 62898	A2	19930628	HU 1992-1704	19920522
	HU 210764	B	19950728		
	JP 05155887	A2	19930622	JP 1992-132526	19920525
PRAI	GB 1991-11130	A	19910523		

OS MARPAT 119:28162
IT 146351-75-9P 146351-76-0P 146351-83-9P
146351-84-0P 146351-85-1P 146351-87-3P
146351-88-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)
RN 146351-75-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(phenylethynyl)- (9CI) (CA INDEX NAME)



RN 146351-76-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 146351-83-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 146351-84-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 146351-85-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(1-hexynyl)- (9CI) (CA INDEX NAME)



RN 146351-87-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-(3-butenyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146351-88-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-hexyl- (9CI) (CA INDEX NAME)


Me— (CH2)5
N
N
O
N
N
N
NH2

L4 ANSWER 116 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:124565 CAPLUS
DN 118:124565
TI Preparation of azolo[1,3,5]triazines as adenosine antagonists
IN Caulkett, Peter William Rodney; Jones, Geraint; Poucher, Simon Martin; Collis, Michael George
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 515108	A2	19921125	EP 1992-304410	19920515
	EP 515108	A3	19930113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	CA 2068747	AA	19921124	CA 1992-2068747	19920515
	US 5246932	A	19930921	US 1992-887211	19920521
	JP 05186471	A2	19930727	JP 1992-132278	19920525
PRAI	GB 1991-11131	A	19910523		

OS MARPAT 118:124565
IT 146229-41-6P 146229-42-7P 146229-43-8P
146229-44-9P 146229-45-0P 146229-46-1P
146229-47-2P 146229-48-3P 146229-49-4P
146229-50-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)
RN 146229-41-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 146229-42-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-2-(2-furanyl)-

(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 146229-43-8 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-[2-[4-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-7-(2-furanyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 146229-44-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-7-(2-furanyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 146229-45-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[3-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 146229-46-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146229-47-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146229-48-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146229-49-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-[2-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 146229-50-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5,N5'-1,6-hexanediylbis[2-(2-furanyl)- (9CI) (CA INDEX NAME)



IT 139180-30-6P 139180-90-8P 139181-09-2P
139181-18-3P 146229-53-0P 146229-54-1P
146229-55-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for adenosine antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-90-8 CAPLUS
CN Phenol, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-09-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-18-3 CAPLUS
CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 146229-53-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 146229-54-1 CAPLUS
CN Phenol, 4-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 146229-55-2 CAPLUS
CN Phenol, 2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



IT 146229-56-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of adenosine antagonist)
RN 146229-56-3 CAPLUS
CN Phenol, 2-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 117 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:581688 CAPLUS
DN 117:181688
TI Pyrazolotriazine photographic cyan coupler for stable image
IN Kaneko, Yutaka; Kita, Hiroshi; Ikesu, Satoru
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04156452	A2	19920528	JP 1990-279200	19901019
PRAI JP 1990-279200		19901019		

IT 143543-10-6 143543-14-0 143543-15-1
143543-16-2 143543-23-1
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 143543-10-6 CAPLUS
CN 1-Dodecanesulfonamide, N-[4-[1,4-dihydro-2-methyl-4-(methylimino)pyrazolo[1,5-a]-1,3,5-triazin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 143543-14-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 8-chloro-7-[4-(dodecyloxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 143543-15-1 CAPLUS
CN Tetradecanamide, N-[4-(4-amino-8-chloro-2-methylpyrazolo[1,5-a]-1,3,5-triazin-7-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 143543-16-2 CAPLUS
CN 1-Dodecanesulfonamide, N-[2-[8-chloro-4-(methylamino)-2-(phenylmethyl)pyrazolo[1,5-a]-1,3,5-triazin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 143543-23-1 CAPLUS
CN Tetradecanoic acid, 4-(4-amino-8-chloro-2-methylpyrazolo[1,5-a]-1,3,5-triazin-7-yl)phenyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 118 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:571476 CAPLUS
DN 117:171476
TI Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-a]triazines and related compounds as adenosine A2 receptor antagonists
IN Caulkett, Peter William Rodney; Jones, Geraint; Collis, Michael George; Poucher, Simon Martin
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 459702	A1	19911204	EP 1991-304665	19910523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	GB 2244487	A1	19911204	GB 1991-11132	19910523
	GB 2244487	B2	19940202		
	CA 2043424	AA	19911130	CA 1991-2043424	19910528
	FI 9102563	A	19911130	FI 1991-2563	19910528
	NO 9102051	A	19911202	NO 1991-2051	19910528
	NO 178401	B	19951211		
	NO 178401	C	19960320		
	AU 9177348	A1	19911205	AU 1991-77348	19910528
	AU 642494	B2	19931021		
	RO 109542	B1	19950330	RO 1991-147639	19910528
	PL 167014	B1	19950731	PL 1991-290445	19910528
	CN 1056879	A	19911211	CN 1991-103744	19910529
	ZA 9104094	A	19920226	ZA 1991-4094	19910529
	HU 61311	A2	19921228	HU 1991-1789	19910529
	JP 05097855	A2	19930420	JP 1991-235332	19910529
	IL 98316	A1	19950526	IL 1991-98316	19910530
PRAI	GB 1990-11913	A	19900529		
	GB 1990-11914	A	19900529		
	GB 1991-1379	A	19910122		
	GB 1991-1380	A	19910122		
	GB 1991-4125	A	19910227		

OS MARPAT 117:171476
IT 139179-55-8P 139179-77-4P 139179-78-5P
139179-79-6P 139179-82-1P 139179-83-2P
139179-84-3P 139179-85-4P 139179-86-5P
139179-87-6P 139179-88-7P 139179-89-8P
139179-90-1P 139179-91-2P 139180-03-3P
139180-04-4P 139180-12-4P 139180-13-5P
139180-15-7P 139180-16-8P 139180-17-9P
139180-18-0P 139180-19-1P 139180-20-4P
139180-21-5P 139180-22-6P 139180-23-7P
139180-24-8P 139180-25-9P 139180-26-0P
139180-27-1P 139180-28-2P 139180-29-3P
139180-30-6P 139180-31-7P 139180-65-7P
139180-67-9P 139180-82-8P 139180-83-9P
139180-84-0P 139180-85-1P 139180-86-2P
139180-87-3P 139180-88-4P 139180-90-8P
139180-96-4P 139180-97-5P 139180-98-6P
139180-99-7P 139181-05-8P 139181-07-0P
139181-08-1P 139181-09-2P 139181-10-5P
139181-11-6P 139181-12-7P 139181-13-8P
139181-17-2P 139181-18-3P 139181-20-7P
139181-21-8P 139181-25-2P 139211-51-1P
139211-52-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine A2 receptor antagonist)

RN 139179-55-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-propyl- (9CI) (CA INDEX NAME)



RN 139179-77-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139179-78-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-phenyl- (9CI) (CA INDEX NAME)



RN 139179-79-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-2-propenyl- (9CI) (CA INDEX NAME)



RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 139179-83-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-butyl-2-(2-furanyl)-(9CI) (CA INDEX NAME)



RN 139179-84-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-ethyl-2-(2-furanyl)-(9CI) (CA INDEX NAME)



RN 139179-85-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 139179-86-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 139179-87-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 139179-88-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139179-89-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 139179-90-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5,N5-dimethyl- (9CI) (CA INDEX NAME)



RN 139179-91-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-03-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-04-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(5-chloro-2-furanyl)-N5-cyclohexyl- (9CI) (CA INDEX NAME)



RN 139180-12-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 139180-13-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-propyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 139180-15-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-16-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-pentyl- (9CI) (CA INDEX NAME)



RN 139180-17-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-18-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-(4-chlorophenyl)ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-19-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-bicyclo[2.2.1]hept-2-yl-2-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139180-20-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 139180-21-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(2-fluorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-22-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139180-23-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(1,3-benzodioxol-5-ylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-24-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 139180-25-9 CAPLUS
CN Benzeneacetamide, N-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 139180-26-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 139180-27-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 139180-28-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclopentyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-29-3 CAPLUS
CN Acetic acid, [4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-31-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)



RN 139180-65-7 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(5-methyl-2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-67-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-propyl- (9CI) (CA INDEX NAME)



RN 139180-82-8 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-bicyclo[2.2.1]hept-2-yl-7-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139180-83-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-cyclohexyl-7-(2-furanyl)-(9CI) (CA INDEX NAME)



RN 139180-84-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-phenyl- (9CI) (CA INDEX NAME)



RN 139180-85-1 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-[2-(dimethylamino)ethyl]-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-86-2 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-87-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(1-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-88-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 139180-90-8 CAPLUS
CN Phenol, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-96-4 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, 7-(2-furanyl)-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 139180-97-5 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine, N2-(cyclopropylmethyl)-7-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139180-98-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139180-99-7 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)



RN 139181-05-8 CAPLUS
CN Phenol, 4-[2-[[7-(2-furanyl)-4-(methylamino)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-07-0 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(3-methyl-5-isoxazolyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-08-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 139181-09-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-10-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 139181-11-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 139181-12-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-13-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-17-2 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 139181-18-3 CAPLUS
CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 139181-20-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 139181-21-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(2-ethoxyphenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139181-25-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[(3-fluorophenyl)methyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 139211-51-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(5-methyl-2-furanyl)-N5-propyl- (9CI) (CA INDEX NAME)



RN 139211-52-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-(cyclopropylmethyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 119 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:530664 CAPLUS
DN 101:130664
TI Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogs of the antitumor drug 2,4,6-tris(dimethylamino)-1,3,5-triazine (hexamethylmelamine)
AU Langdon, Simon P.; Simmonds, Richard J.; Stevens, Malcolm F. G.
CS Dep. Pharm., Univ. Aston, Birmingham, B4 7ET, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1984), (5), 993-8
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 101:130664
IT 54807-00-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)
RN 54807-00-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N,N,N',N'-tetramethyl-2-phenyl- (9CI) (CA INDEX NAME)



IT 91892-55-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 91892-55-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N,N,N',N'-tetramethyl-2-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 91892-36-3P 91892-56-7P 91892-57-8P
91892-58-9P 91892-59-0P 91892-60-3P
91892-62-5P 91892-63-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 91892-36-3 CAPLUS
CN Acetamide, N-[2-[5,7-bis(dimethylamino)[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 91892-56-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N,N,N',N'-tetramethyl-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 91892-57-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N,N,N',N'-tetramethyl-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 91892-58-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-chlorophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



RN 91892-59-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(3-chlorophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



RN 91892-60-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(4-chlorophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



RN 91892-62-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(3,5-dinitrophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



RN 91892-63-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-azidophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



IT 91892-54-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, acetylation, and azidation of)
RN 91892-54-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-aminophenyl)-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)


H2N
Me2N
N
N
N
N
N
NMe2

L4 ANSWER 120 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:181036 CAPLUS
DN 96:181036
TI Synthesis and enzymic activity of various substituted pyrazolo[1,5-a]-1,3,5-triazines as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors
AU Senga, Keitaro; O'Brien, Darrell E.; Scholten, Mieka B.; Novinson, Thomas; Miller, Jon P.; Robins, Roland K.
CS Viratek, Inc., Covina, CA, 91722, USA
SO Journal of Medicinal Chemistry (1982), 25(3), 243-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 96:181036
IT 80568-93-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cAMP phosphodiesterase inhibitory activity of)
RN 80568-93-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, N-butyl-2-methyl-7-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 121 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:130132 CAPLUS
DN 84:130132
TI Novel heterocyclic nitrofurfural hydrazones. In vivo antitrypanosomal activity
AU Novinson, Thomas; Bhooshan, Bharat; Okabe, Takayuki; Revankar, Ganapathi R.; Robins, Roland K.; Senga, Keitaro; Wilson, H. Robert
CS Nucleic Acid Res. Inst., ICN Pharm., Inc., Irvine, CA, USA
SO Journal of Medicinal Chemistry (1976), 19(4), 512-16
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 84:130132
IT 58347-43-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antitrypanosomal activity of)
RN 58347-43-6 CAPLUS
CN 2-Furancarboxaldehyde, 5-nitro-, (2-methyl-7-phenylpyrazolo[1,5-a]-1,3,5-triazin-4-yl)hydrazone (9CI) (CA INDEX NAME)



IT 58382-38-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with nitrofurfural)
RN 58382-38-0 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4(1H)-one, 2-methyl-7-phenyl-, hydrazone (9CI) (CA INDEX NAME)



L4 ANSWER 122 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:410160 CAPLUS
DN 83:10160
TI 4-Aminopyrazolo[1,5-a]-s-triazines
IN Vogel, Arnold; Troxler, Franz
PA Sandoz Ltd.
SO Ger. Offen., 74 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2424334	A1	19741219	DE 1974-2424334	19740518
	CH 581137	A	19761029	CH 1973-7259	19730522
	NL 7406641	A	19741126	NL 1974-6641	19740517
	FI 7401461	A	19741123	FI 1974-1461	19740519
	ES 426482	A1	19760901	ES 1974-426482	19740520
	JP 50019769	A2	19750301	JP 1974-56179	19740521
	DD 113907	C	19750712	DD 1974-178657	19740521
	BE 815405	A1	19741122	BE 1974-144632	19740522
	FR 2230366	A1	19741220	FR 1974-17821	19740522
	AU 7469259	A1	19751127	AU 1974-69259	19740522
	ZA 7403316	A	19760128	ZA 1974-3316	19740522
PRAI	CH 1973-7257	A	19730522		
	CH 1973-7258	A	19730522		
	CH 1973-7259	A	19730522		
	CH 1973-16940	A	19731204		
	CH 1974-4425	A	19740329		

IT 54475-77-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54475-77-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 2-methyl-7-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 123 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:125364 CAPLUS
DN 82:125364
TI Synthesis of s-triazolo[4,3-a]-s-triazines and their isomerization to s-triazolo[2,3-a]-s-triazines
AU Deshpande, R. J.; Roa, A. V. Rama
CS Natl. Chem. Lab., Poona, India
SO Synthesis (1974), (12), 863-5
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
IT 54807-00-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54807-00-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N,N,N',N'-tetramethyl-2-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 124 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:43361 CAPLUS
DN 82:43361
TI Synthesis of unsymmetrical 2,4-dialkylpyrazolo[1,5-a]-1,3,5-triazines
AU Novinson, Thomas; Senga, Keitaro; Kobe, Joze; Robins, Roland K.; O'Brien, Darrell E.; Albert, Anthony A.
CS Nucleic Acid. Res. Inst., ICN Pharm., Inc., Irvine, CA, USA
SO Journal of Heterocyclic Chemistry (1974), 11(5), 691-5
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 82:43361
IT 54475-77-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54475-77-3 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 2-methyl-7-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 125 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:487897 CAPLUS
DN 73:87897
TI 2-Substituted 7-amino-1,2,4-triazolo[1,5-a]-1,3,5-triazines
AU Bokaldere, R.; Grinsteins, V.
CS Inst. Org. Sin., Riga, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1970), (4), 563-4
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian
IT 28610-05-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28610-05-1 CAPLUS
CN s-Triazolo[1,5-a]-s-triazine, 5,7-diamino-2-phenyl- (8CI) (CA INDEX NAME)



L4 ANSWER 126 OF 126 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:11437 CAPLUS
DN 54:11437
OREF 54:2332i,2333a-i,2334a-f
TI Derivatives of 5-aminopyrazole. IV. Synthesis of heterocyclic derivatives
AU Checchi, Silvio; Ridi, Mario
CS Univ. Florence
SO Gazzetta Chimica Italiana (1957), 87, 597-614
CODEN: GCITA9; ISSN: 0016-5603
DT Journal
LA Unavailable
IT 109411-93-0, Pyrazolo[1,5-a]-s-triazine, 2,4-diacetamido-7-phenyl-
115231-49-7, Pyrazolo[1,5-a]-s-triazine, 1,2,3,4-tetrahydro-2,4-diimino-7-phenyl-
(preparation of)
RN 109411-93-0 CAPLUS
CN Pyrazolo[1,5-a]-s-triazine, 2,4-diacetamido-7-phenyl- (6CI) (CA INDEX NAME)



RN 115231-49-7 CAPLUS
CN Pyrazolo[1,5-a]-s-triazine, 1,2,3,4-tetrahydro-2,4-diimino-7-phenyl- (6CI) (CA INDEX NAME)



11/449,613

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	443.18	610.77

STN INTERNATIONAL LOGOFF AT 12:07:15 ON 27 NOV 2006